ATLAS ANTIBODIES IN BREAST CANCER RESEARCH

ATLAS ANTIBODIES

TABLE OF CONTENTS

THE HUMAN PROTEIN ATLAS

The Human Protein Atlas: a map of the Human Proteome

The Human Protein Atlas (HPA) is a Swedish-based program initiated in 2003 with the aim to map all the human proteins in cells, tissues and organs using integration of various omics technologies, including antibody-based imaging, mass spectrometry-based proteomics, transcriptomics and systems biology.

All the data in the knowledge resource is open access to allow scientists both in academia and industry to freely access the data for exploration of the human proteome.

The HPA project aims to present an expression map of the complete human proteome. To accomplish this, highly specific Triple A polyclonal antibodies are developed against all protein-coding human genes and protein profiling is established in a multitude of tissues and cells using tissue arrays. The antibodies are tested in immunohistochemistry (IHC), Western blot (WB) analysis, protein array assay and immunofluorescent based confocal microscopy (ICC-IF).

The Human Protein Atlas program has already contributed to several thousands of publications in the field of human biology and disease and it is selected by the organization ELIXIR (www.elixir-europe.org) as a European core resource due to its fundamental importance for a wider life science community.

The HPA project employs tissue microarrays with samples from 44 different normal human tissues, 20 different cancer types and 44 different human cell lines. The 44 normal tissues are present in triplicate samples and represent 82 different cell types. All the IHC images for the normal tissue have undergone pathology-based annotation of expression levels.

The Human Protein Atlas consortium is mainly funded by the Knut and Alice Wallenberg Foundation.

Read more at proteinatlas.org

The Human Protein Atlas consists of 10 separate parts, each focusing on a particular aspect of the genome-wide analysis of the human proteins:

1. TISSUE
The Tissue section shows the distribution of the proteins across all primary tissues and organs in the human body.

2. BRAIN
The Brain section explores the distribution of proteins in various mammalian brain regions.

3. SINGLE-CELL TYPE
The Single Cell Type section shows the expression of protein-coding genes in single human cell types based on scRNA-seq.

4. PATHOLOGY
The Pathology section shows the impact of protein levels on the survival of patients with cancer.

5. BLOOD PROTEIN
The Blood Protein section, describes the proteins detected in the blood and proteins secreted by human tissues.

6. TISSUE CELL TYPE
The Tissue Cell Type section shows the expression of protein-coding genes in human cell types based on bulk RNA-seq data.

7. IMMUNE CELL
The Immune Cell section shows the expression of protein-coding genes in immune cell types.

8. SUBCELLULAR
The Subcellular section shows the subcellular localization of proteins in single cells.

9. CELL LINE
The Cell Line section shows the expression of protein-coding genes in human cell lines.

10. METABOLIC
The Metabolic section explores the expression of protein-coding genes in the context of the human metabolic network.

Triple A Polyclonals™

Triple A Polyclonals - the Building Blocks of HPA

The uniqueness and specificity of Triple A Polyclonals are due to a thorough selection of antigen regions, affinity purification on the recombinant antigen, validation using several methods and a stringent approval process.

Development

The Triple A Polyclonals are developed against recombinant human Protein Epitope Signature Tags (PrESTs) of approximately 50 to 150 amino acids. These protein fragments are designed, using a proprietary software, to contain unique epitopes present in the native protein suitable for triggering the generation of antibodies of high specificity. This is achieved by a complete human genome scanning to ensure that PrESTs with the lowest homology to other human proteins are used as antigens.

Approval

The approval of the Triple A Polyclonals relies on a combined validation of the experimental results using IHC, WB or ICC-IF, from RNA sequencing and from information obtained via bioinformatics prediction methods and literature.

Since the literature is often inconclusive, an important objective of the HPA project has been to generate paired antibodies with non-overlapping epitopes towards the same protein target, allowing the results and validation of one antibody to be used to validate the other one.

Triple A Polyclonal catalog

Today, there are more than 21,000 Triple A Polyclonals.

The antibodies developed and characterized within the Human Protein Atlas project are made available to the scientific community by Atlas Antibodies under the brand name Triple A Polyclonals. The antibodies are available in 25 and 100 µL size. The product numbers of Triple A Polyclonals start with "HPA".

PrecisA Monoclonals™

PrecisA Monoclonals are mouse monoclonal primary antibodies developed for a number of carefully selected targets. Atlas Antibodies selects the relevant antibodies for each target and takes special care in offering clones recognizing unique non-overlapping epitopes and/or isotypes.

Thanks to a stringent production process and characterization procedure, PrecisA Monoclonals provide outstanding performance in approved applications, defined specificity, secured continuity, and stable supply.

Antigen Selection

The Protein Epitope Signature Tag (PrEST) concept gives the antibody performance built-in from the start. Using proprietary bioinformatics software, 50-150 amino acid regions (with the lowest possible sequence identity to other human proteins) are selected, cloned, and recombinantly produced in a tightly controlled set-up.

Epitope Mapping

Clones are epitope-mapped using synthetic overlapping peptides in a bead-based array format to select clones with non-overlapping epitopes only.

Hybridoma Cell Cultivation

Atlas Antibodies uses in-vitro methods in the production scale-up phase, thus replacing mice for ascites fluid production.

Isotyping

PrecisA Monoclonals are isotyped to allow for multiplexing using isotype-specific secondary antibodies.

Antibody Characterization

The characterization of PrecisA Monoclonals starts with an extensive literature search to select the most relevant and clinically significant tissues to use for immunohistochemistry (IHC) characterization. As a result, you will often find more than one tissue type displayed in the IHC application data in our product catalog. In addition to the positive stained tissue, we also show the staining in a negative control tissue and, if relevant, staining in cancerous tissue.

The characterization for Western Blot (WB) data follows that same working procedure. It starts with a profound literature search to find the best matching lysate, which can be endogenous human cells, tissue protein lysates, or optionally recombinant full-length human protein lysates.

Each PrecisA Monclonal is thus supplied with the most appropriate characterization data for its specific target.

PrecisA Monoclonals are developed by Atlas Antibodies, based on the knowledge from the Human Protein Atlas with careful antigen design and extended validation of antibody performance. With precise epitope information following all monoclonals, these precise, accurate and targeted antibodies are denoted PrecisA Monoclonals. The antibodies are available in 25 and 100 µL size. The product numbers of PrecisA Monclonals start with "AMAb".

Established clinical breast cancer markers: ESR1, HER2, Ki67, PGR

Target protein	Product Name	Product Number	Validated Applications
Estrogen receptor	Anti-ESR1	HPA000449[1]	IHC*,WB*,ICC-IF
Estrogen receptor	Anti-ESR1	HPA000450[1]	IHC*,WB*
Estrogen receptor	Anti-ESR1	AMAb90867	IHC,WB*,ICC-IF
Progesteron receptor	Anti-PGR	HPA004751[2]	IHC*
Progesteron receptor	Anti-PGR	HPA008428[3]	IHC*
Progesteron receptor	Anti-PGR	HPA017176	IHC*
HER2/ERBB2	Anti-ERBB2	HPA001383[3,4]	IHC,WB,ICC-IF
HER2/ERBB2	Anti-HER2	AMAb90627	IHC,WB
Ki67/MKI67	Anti-MKI67	HPA000451[5,6]	IHC*,ICC-IF
Ki67/MKI67	Anti-MKI67	HPA001164[7]	IHC*,ICC-IF
Ki67/MKI67	Anti-MKI67	AMAb90870	IHC,ICC-IF

* Products with enhanced validation for indicated application

1. Algenäs C et al. Antibody performance in western blot applications is context-dependent. Biotechnol J 2014 Mar; 9(3):435-45.

2. Pereira CB et al. Prognostic and Predictive Significance of MYC and KRAS Alterations in Breast Cancer from Women Treated with Neoadjuvant Chemotherapy. PLoS One 2013;8(3):e60576.

3. Huvila J et al. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Gynecol Oncol 2013 Sep; 130(3):463-9.

4. Newie I et al. The HER2-Encoded miR-4728-3p Regulates ESR1 through a Non-Canonical Internal Seed Interaction. PLoS One 2014; 9(5):e97200.

5. Li S et al. Endothelial VEGF Sculpts Cortical Cytoarchitecture. J Neurosci 2013 Sep 11; 33(37):14809-14815.

6. Pohler E et al. Haploinsufficiency for AAGAB causes clinically heterogeneous forms of punctate palmoplantar keratoderma. Nat Genet. 2012 Nov; 44(11):10.1038/ng.2444.

7. Roca H et al. IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin upregulation. J Cell Biochem 2012 May; 113(5):1569-1580.

Estrogen receptor

(A) IHC staining with the Anti-ESR1 antibody (HPA000449) shows distinct nuclear positivity in glandular cells in human breast tissue and (B) in tumor cells in breast cancer samples.


(A) IHC staining using the Anti-ESR1 antibody (HPA000450) shows strong nuclear positivity in glandular and stromal cells of human corpus, uterine tissue and (B) in tumor cells in breast cancer.

HER2/ERBB2

(A) IHC staining of human breast tumour using Anti-HER2 (AMAb90627) shows strong membranous (combined with moderate cytoplasmic) positivity in tumour cells in HER2-positive ductal carcinoma (in brown), (B) HER2-negative ductal carcinoma shows no membranous positivity. (C) HER2 is detected in the breast cancer cell line SK-BR-3 by Western blot analysis.

Progesteron receptor

(A) IHC staining using the Anti-PGR antibody (HPA004751) in normal human corpus (uterine) tissue shows strong nuclear positivity in glandular cells (in brown). (B) Staining of tumor cells in breast cance shows strong nuclear positivity (in brown). (C) ICC-IF shows nuclear staining in U-251MG cells (in green).

Ki67

(A) The Anti-MKI67 antibody (HPA000451) shows strong nuclear positivity in a fraction of cells in the reaction center in human lymph node using IHC. (B) In breast cancer, the staining of tumor cells is also nuclear. (C) ICC-IF staining of the human cell line U-2OS shows positivity in nucleoli (in green).


(A) IHC staining of human tonsil tissue using the Anti-MKI67 antibody (HPA001164) shows nuclear staining of reaction center cells. (B) In tumor cells in breast cancer, the staining is mainly nuclear. (C) ICC-IF in U-2OS cells show strong positivity in nucleoli (green).


(A) IHC staining of lymph node in human colon shows strong nuclear and nucleolar immunoreactivity in the reaction centrum cells using the monoclonal Anti-MKI67 antibody (AMAb90870). (B) nuclear positivity in a subset of glandular cells in human uterus.

Antibodies used in Breast Cancer Research

In this section, antibodies are selected either based on a published reference or for the relevance in breast cancer of the corresponding target protein.

Target Protein	Product Name	Product Number	Validated Applications
53BP1	Anti-TP53BP1	HPA008788	WB,ICC-IF
53BP1	Anti-TP53BP1	HPA022133	IHC,WB*,ICC-IF
ACAT1	Anti-ACAT1	HPA004428[1]	IHC*,WB*,ICC-IF
ACAT1	Anti-ACAT1	HPA007569[2-4]	IHC*,WB*,ICC-IF
ADAM2/CT15/PH30	Anti-ADAM2	HPA026581[5]	IHC*
AGR2	Anti-AGR2	HPA007912[6]	IHC*,WB*,ICC-IF
AIB1/NCOA3	Anti-NCOA3	HPA024210[7]	IHC,WB,ICC-IF
AKAP1/PRKA1	Anti-AKAP1	HPA008691[8]	IHC,WB*
AKT3/PKB gamma	Anti-AKT3	HPA026441[9,10]	IHC,WB
AMOTL1	Anti-AMOTL1	HPA001196[11]	IHC,ICC-IF
Amphiregulin	Anti-AREG	HPA008720[12]	IHC
ANAPC15/C11orf51	Anti-ANAPC15	HPA036596	IHC,WB*,ICC-IF
Anillin/ANLN	Anti-ANLN	AMAb90660	IHC*,WB,ICC-IF
Anillin/ANLN	Anti-ANLN	AMAb90662	IHC*,WB*,ICC-IF
Anillin/ANLN	Anti-ANLN	HPA005680[13,14]	IHC*,WB*
ARG1	Anti-ARG1	HPA024006[15-17]	IHC*,WB*
ARG1	Anti-ARG1	AMAb90545	IHC,WB
ASAH1	Anti-ASAH1	HPA005468[18-22]	IHC,WB*
BAAT1/BRAT1	Anti-BRAT1	HPA029455	IHC,WB*
BARD1	Anti-BARD1	HPA044864	IHC*
Beta-Catenin	Anti-CTNNB1	HPA029159	IHC*,WB,ICC-IF
Beta-Catenin	Anti-CTNNB1	HPA029160	IHC*,ICC-IF
Beta-Catenin	Anti-CTNNB1	AMAb91210	IHC,WB,ICC-IF
BIRC3/API2	Anti-BIRC3	HPA002317[23-25]	IHC,WB,ICC-IF

* Products with enhanced validation for indicated application

ACAT1

(A) IHC staining of human liver tissue using Anti-ACAT1 (HPA004428) shows strong cytoplasmic positivity in hepatocytes (in brown). (B) By Western blot analysis, ACAT1 is detected in the human cell lines RT-4 and U251-MG and in liver and tonsil tissue lysates. (C) By ICC-IF in the human cell line A-431, positivity is shown in mitochondria (in green).

1. Sanchez-Alvarez R *et al*. Ethanol exposure induces the cancer-associated fibroblast phenotype and lethal tumor metabolism: Implications for breast cancer prevention. *Cell Cycle* 2013 Jan 15; 12(2):289-301.

2. Martinez-Outschoorn UE *et al*. Ketone bodies and two-compartment tumor metabolism: Stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. *Cell Cycle* 2012 Nov 1; 11(21):3956-3963.

3. Martinez-Outschoorn UE *et al*. Ketone body utilization drives tumor growth and metastasis. *Cell Cycle* 2012 Nov 1;11(21):3964-71.

4. Chang HT *et al*. Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet therapy. *Nutr Metab* (Lond) 1047. Epub 2013/07/05.

5. Maheswaran E *et al*. Lack of ADAM2, CALR3 and SAGE1 Cancer/Testis Antigen Expression in Lung and Breast Cancer. *PLoS One* 2015; 10(8):e0134967. Epub 2015 Aug 7.

6. Hrstka R *et al*. AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients. *Dis Markers* 2013; 35(4):207-212.

7. Battistella M *et al*. The High Expression of the microRNA 17–92 Cluster and its Paralogs, and the Downregulation of the Target Gene PTEN, Is Associated with Primary Cutaneous B-Cell Lymphoma Progression. *Journal of Investigative Dermatology* January 29, 2015.

8. Sotgia F *et al*. Mitochondria "fuel" breast cancer metabolism: Fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. *Cell Cycle* 2012 Dec 1; 11(23):4390-4401.

9. O'Hurley G *et al*. Investigation of molecular alterations of AKT-3 in triple-negative breast cancer. *Histopathology* 2014 Apr; 64(5):660-70.

10. Vredeveld LC *et al*. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. *Genes Dev* 2012 May 15; 26(10):1055-1069.

11. Couderc C *et al*. AMOTL1 Promotes Breast Cancer Progression and Is Antagonized by Merlin. *Neoplasia* 2016 Jan; 18(1):10-24.

12. Barton VN *et al*. Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo. *Mol Cancer Ther* 2015 Mar; 14(3):769-778.

13. O´Leary PC *et al*. Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer. *BMC Cancer.* 2013 Apr 2;13:175.

14. Hjelm B *et al*. Generation of monospecific antibodies based on affinity capture of polyclonal antibodies. *Protein Sci.* 2011 Nov; 20(11):1824-35.

15. de Boniface J *et al*. Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients. *Oncoimmunology* 2012 Nov 1; 1(8):1305-1312.

16. Hashimoto-Kataoka T *et al*. Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. *Proc Natl Acad Sci U S A* 2015 May 19; 112(20):E2677-E2686.

17. Geiger T *et al*. Initial Quantitative Proteomic Map of 28 Mouse Tissues Using the SILAC Mouse. *Mol Cell Proteomics* 2013 Jun; 12(6):1709-1722.

18. Lucki NC *et al*. Acid Ceramidase (ASAH1) Represses Steroidogenic Factor 1-Dependent Gene Transcription in H295R Human Adrenocortical Cells by Binding to the Receptor. *Mol Cell Biol* 2012 Nov; 32(21):4419-4431.

19. Cai K *et al*. Silencing diacylglycerol kinase-theta expression reduces steroid hormone biosynthesis and cholesterol metabolism in human adrenocortical cells. *Biochim Biophys Acta* 2014 Apr 4; 1841(4):552-562.

20. Lucki NC *et al*. Acid Ceramidase (ASAH1) Is a Global Regulator of Steroidogenic Capacity and Adrenocortical Gene Expression. *Mol Endocrinol* 2012 Feb; 26(2):228-243.

21. Lucki NC and Sewer MB. Genistein Stimulates MCF-7 Breast Cancer Cell Growth by Inducing Acid Ceramidase (ASAH1) Gene Expression. *J Biol Chem* 2011 Jun 3; 286(22):19399-19409.

22. Lucki NC and Sewer MB. AThe cAMP-responsive element binding protein (CREB) regulates the expression of acid ceramidase (ASAH1) in H295R human adrenocortical cells. *Biochim Biophys Acta* 2009 Aug; 1791(8):706-713.

23. Jones DR *et al*. APhase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non-small Cell Lung Cancer. *J Thorac Oncol* 2012 Nov; 7(11):1683-1690.

24. Almubarak H *et al*. Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. *J Carcinog* 2011 Jan 15; 10:2.

25. Mulder J *et al*. Tissue Profiling of the Mammalian Central Nervous System Using Human Antibody-based Proteomics. *Mol Cell Proteomics* 2009 Jul; 8(7):1612-1622.

Target Protein	Product Name	Product Number	Validated Applications
BIT1/ PTRH2	Anti-PTRH2	HPA012897[26-28]	IHC,WB,ICC-IF
Blooms Syndrome Prot	Anti-BLM	HPA005689[29-30]	IHC,ICC-IF
Bmi1	Anti-BMI1	HPA030472	IHC,WB*
BRCA2	Anti-BRCA2	HPA026815	ICC-IF
BRIP1/FANCJ	Anti-BRIP1	HPA005474[32]	IHC,WB*,ICC-IF
CASP8	Anti-CASP8	HPA001302	IHC,WB,ICC-IF
CASP8	Anti-CASP8	HPA005688	IHC,WB
CAXII/CA12	Anti-CA12	HPA008773[33-36]	IHC,ICC-IF
CAXII/CA12	Anti-CA12	AMAb90639	IHC,WB
CD44	Anti-CD44	HPA005785[37-43]	IHC,WB*,ICC-IF
CD82	Anti-CD82	HPA028900	IHC*,WB*
CDH1	Anti-CDH1	AMAb90863	IHC*,WB*
CDH1	Anti-CDH1	HPA004812	IHC*
CEA/CEACAM5	Anti-CEACAM5	HPA019758	IHC*,WB,ICC-IF
CHEK2	Anti-CHEK2	HPA001878	IHC,WB*,ICC-IF
CKB	Anti-CKB	HPA001254[44,45]	IHC*,ICC-IF
CRABP2	Anti-CRABP2	HPA004135[46]	IHC,WB*,ICC-IF
CT83/KK-LC-1	Anti-CT83	HPA004773[47]	IHC,WB
CTNND1	Anti-CTNND1	HPA015955	IHC,WB*,ICC-IF
Cyclin E1	Anti-CCNE1	HPA018169[48]	IHC,ICC-IF
cyklin A2	Anti-CCNA2	HPA020626	WB*,ICC-IF
Cytokeratin 14/CK14	Anti-KRT14	HPA023040	IHC*,WB
Cytokeratin 17/CK17	Anti-KRT17	HPA000452[49]	IHC,WB*,ICC-IF
Cytokeratin 17/CK17	Anti-KRT17	HPA000453	IHC*,WB*

* Products with enhanced validation for indicated application

26. Brunquell C et al. TLE1 is an anoikis regulator and is downregulated by Bit1 in breast cancer cells. Mol Cancer Res 2012 Nov; 10(11):1482-1495.

27. Karmali PP et al. Metastasis of tumor cells is enhanced by downregulation of bit1. PLoS One 2011;6(8):e23840.

28. Yao X et al. The Anoikis Effector Bit1 Displays Tumor Suppressive Function in Lung Cancer Cells. PLoS One 2014; 9(7):e101564.

29. Meena JK et al. Telomerase abrogates aneuploidy-induced telomere replication stress, senescence and cell depletion. EMBO J 2015 May 12; 34(10):1371-1384.

30. Lao VV et al. Altered RECQ Helicase Expression in Sporadic Primary Colorectal Cancers. Transl Oncol 2013 Aug; 6(4):458-469.

31. Chiang SC et al. Prioritization of Cancer Marker Candidates Based on the Immunohistochemistry Staining Images Deposited in the Human Protein Atlas. PLoS One 2013; 8(11):e81079.

32. Zou W et al. BRIP1 inhibits the tumorigenic properties of cervical cancer by regulating RhoA GTPase activity. Oncol Lett 2016/01/01; 11(1):551-558.

CD44

(A) IHC staining of human esophagus tissue using Anti-CD44 (HPA005785) shows strong cytoplasmic and membranous positivity in squamous epithelial cells (in brown). (B) By Western blot analysis, CD44 is detected in the human cell line U-251MG. (C) ICC-IF in the human cell line U-251MG shows positivity in plasma membrane (in green).

BRCA1

IHC staining with the Anti-BRCA1 antibody (HPA034966) shows positivity in glandular cells in normal human breast tissue (A) and in tumor cells (B) in breast cancer samples using IHC.

BRCA2

(A) IHC staining using the Anti-BRCA2 antibody (HPA026815) shows positivity in glandular cells in normal human breast tissue (B) In breast cancer tissue, staining of tumor cells is nuclear (in brown).

33. Vermeulen JF et al. Immunophenotyping invasive breast cancer: paving the road for molecular imaging. BMC Cancer 12240.

34. Davidson B et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med 2011 Mar;15(3):535-44.

35. Vermeulen et al. Differential expression of growth factor receptors and membrane-bound tumor markers for imaging in male and female breast cancer. PLoS One 2013;8(1):e53353.

36. Tafreshi NK et al. Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probes. Clin Cancer Res 2012 Jan 1;18(1):207-19.

37. Vazquez-Martin A et al. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 2010 Sep 15;9(18):3807-14.

38. Baccelli I et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013 Apr 21;

39. Petit V et al. Optimization of tumor xenograft dissociation for the profiling of cell surface markers and nutrient transporters. Lab Invest 2013 May;93(5):611-21.

40. Twarock S et al. Synthesis of hyaluronan in oesophageal cancer cells is uncoupled from the prostaglandin-cAMP pathway. Br J Pharmacol 2009 May;157(2):234-43.

41. Asplund A et al. Expression profiling of microdissected cell populations selected from basal cells in normal epidermis and basal cell carcinoma. Br J Dermatol 2008 Mar;158(3):527-38.

42. Ma R et al. Superficial scrapings from breast tumors is a source for biobanking and research purposes. Laboratory Investigation 2014 94, 796-805.

43. Schneck H et al. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer. PLoS One 1/01/01; 10(12):e0144535.

44. Mello AA et al. Deregulated Expression of SRC, LYN and CKB Kinases by DNA Methylation and Its Potential Role in Gastric Cancer Invasiveness and Metastasis. PLoS One 2015; 10(10):e0140492.

45. Bachmann J et al. Affinity Proteomics Reveals Elevated Muscle Proteins in Plasma of Children with Cerebral Malaria. PLoS Pathog 2014 Apr; 10(4):e1004038.

46. Seidensaal K et al. Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma. Mol Cancer 2015/12/03; 14:204.

47. Paret C et al. CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer. Oncotarget 2015 Sep 22; 6(28):25356-25367.

48. Fu YP et al. The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease. Cancer Res 2014 Oct 15; 74(20):5808-5818.

49. Kiflemariam S et al. Scalable in situ hybridization on tissue arrays for validation of novel cancer and tissue-specific biomarkers. PLoS One 2012;7(3):e32927.

Target Protein	Product Name	Product Number	Validated Applications
DACH2	Anti-DACH2	HPA000258[50]	IHC
DBC1/KIAA1967	Anti-KIAA1967	HPA019907	IHC*,WB*,ICC-IF
DBC1/KIAA1967	Anti-KIAA1967	HPA019943	IHC*,WB*
DCAF7	Anti-DCAF7	HPA022962[51]	IHC*,WB*
DDX43/CT13	Anti-DDX43	HPA031381[52]	IHC*,WB
Decorin/DCN	Anti-DCN	HPA003315[53-56]	IHC*,WB
DIRAS3	Anti-DIRAS3	HPA028483	IHC,WB*
DIRAS3	Anti-DIRAS3	HPA028557	IHC,ICC-IF
DIRAS3	Anti-DIRAS3	HPA029384	IHC
DKC1	Anti-DKC1	HPA000166[57-59]	IHC,WB
EGFR	Anti-EGFR	AMAb90816	IHC,WB
EGFR	Anti-EGFR	AMAb90819	WB
EGFR	Anti-EGFR	HPA001200[62]	IHC*
EGFR	Anti-EGFR	HPA018530[63,64]	IHC*,WB,ICC-IF
Endoplasmin/ HSP90B1	Anti-HSP90B1	HPA003901[54,65]	IHC,WB*,ICC-IF
Endoplasmin/ HSP90B1	Anti-HSP90B1	AMAb91019	IHC,WB*,ICC-IF
EPSTI1	Anti-EPSTI1	HPA017362[66]	IHC
ERLIN2	Anti-ERLIN2	HPA002025[67,68]	IHC,WB,ICC-IF
ERFF/C1orf64	Anti-C1orf64	HPA026676[69]	IHC,WB*
FAAH	Anti-FAAH	HPA007425[70]	IHC
FGFR2	Anti-FGRF2	HPA035305[71]	IHC
G3BP-2	Anti-G3BP2	HPA018304[72]	IHC*,ICC-IF
GATA3	Anti-GATA3	HPA029731	IHC
GGH	Anti-GGH	HPA025226[70]	IHC,WB*
GOLPH3/MIDAS	Anti-GOLPH3	HPA044564[8]	IHC
GP2	Anti-GP2	HPA016668[73]	IHC*
GPAT2	Anti-GPAT2	HPA036841[74,75]	IHC, ICC-IF

* Products with enhanced validation for indicated application

EGFR

(A) IHC staining using the Anti-EGFR antibody (HPA018530) in normal human placenta tissue shows strong positivity in trophoblasts (brown). (B) ICC-IF in human cell line A-431, shows strong staining of plasma membrane (in green).

Endoplasmin

(A) IHC staining using the Anti-HSP90B1 antibody (AMAb91019) in normal human prostate shows strong cytoplasmic positivity in glandular cells (in brown). (B) ICC-IF in human cell line A-431, shows strong positivity in endoplasmic reticulum (in green).

50. Nodin B *et al.* Discovery of dachshund 2 protein as a novel biomarker of poor prognosis in epithelial ovarian cancer. *J Ovarian Res* 2012 Jan 27;5(1):6.

51. Sircoulomb F *et al.* ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. *EMBO Mol Med* 2011 Mar; 3(3):153-166.

52. Abdel-Fatah TM *et al.* HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer. *Br J Cancer* 2014 May 13; 110(10):2450-2461.

53. Henke A *et al.* Stromal Expression of Decorin, Semaphorin6D, SPARC, Sprouty1 and Tsukushi in Developing Prostate and Decreased Levels of Decorin in Prostate Cancer. *LoS One* 7(8):e42516.

54. Cawthorn TR *et al.* Proteomic Analyses Reveal High Expression of Decorin and Endoplasmin (HSP90B1) Are Associated with Breast Cancer Metastasis and Decreased Survival. *PLoS One* 2012;7(2):e30992.

55. Bozoky B *et al.* Decreased decorin expression in the tumor microenvironment. *Cancer Med* 2014 Jun; 3(3):485-491.

56. Edlund K *et al.* CD99 is a novel prognostic stromal marker in non-small cell lung cancer. *Int J Cancer* 2012 Nov 15; 131(10):2264-73.

57. Montanaro L *et al.* Relationship between dyskerin expression and telomerase activity in human breast cancer. *Cell Oncol* 2008; 30(6):483-90.

58. Koskimaa HM *et al.* Molecular markers implicating early malignant events in cervical carcinogenesis. *Cancer Epidemiol Biomarkers Prev* 2010 Aug; 19(8):2003-12.

59. Sieron P *et al.* DKC1 overexpression associated with prostate cancer progression. *Br J Cancer* 2009 Oct 20; 101(8):1410-6.

60. Johansson J *et al.* TGF-β1-Induced Epithelial–Mesenchymal Transition Promotes Monocyte/Macrophage Properties in Breast Cancer Cells. *Front Oncol* 2015; 5:3.

61. Jabara HH *et al.* DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. *Nat Immunol* 2012 May 13; 13(6):612-20.

62. Hudson EP *et al.* Multiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes. *Sci Rep* 2012;2:706.

63. Arabi A *et al.* Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway. *Nat Commun* 2012;3:976.

64. Luke GP *et al.* Sentinel lymph node biopsy revisited: ultrasound-guided photoacoustic detection of micrometastases using molecularly targeted plasmonic nanosensors. *Cancer Res* 2014 Oct 1; 74(19):5397-5408.

65. Ito A *et al.* Novel application for pseudopodia proteomics using excimer laser ablation and two-dimensional difference gel electrophoresis. *Lab Invest* 2012 Sep;92(9):1374-85.

66. Li T *et al.* Identification of epithelial stromal interaction 1 as a novel effector downstream of Krüppel-like factor 8 in breast cancer invasion and metastasis. *Oncogene* 2014 Sep 25; 33(39):4746-4755.

67. Holland DG *et al.* ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. *EMBO Mol Med* 2011 Mar;3(3):167-80.

68. Mulder J *et al.* Tissue profiling of the mammalian central nervous system using human antibody-based proteomics. *Mol Cell Proteomics* 2009 Jul;8(7):1612-22.

69. Su D *et al.* Role of ERRF, a Novel ER-Related Nuclear Factor, in the Growth Control of ER-Positive Human Breast Cancer Cells. *Am J Pathol* 2012 Mar; 180(3):1189-1201.

70. Shubbar E *et al.* High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer. *BMC Cancer* 2013 Feb 1;13:47.

71. Tchaicha JH *et al.* Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a pan-FGFR inhibitor in a mouse model of NSCLC. *Cancer Res* 2013 Feb 1;13:47.

72. Katz E *et al.* Targeting of Rac GTPases blocks the spread of intact human breast cancer. *Oncotarget* 2012 Jun; 3(6):608-619.

73. Muraoka S *et al.* Strategy for SRM-based verification of biomarker candidates discovered by iTRAQ method in limited breast cancer tissue samples. *J Proteome Res* 2012 Aug 3; 11(8):4201-10.

74. Pellon-Maison M *et al.* Glycerol-3-Phosphate Acyltranferase-2 Behaves as a Cancer Testis Gene and Promotes Growth and Tumorigenicity of the Breast Cancer MDA-MB-231 Cell Line. *PLoS One* 2014; 9(6):e100896.

75. Cattaneo ER *et al.* Glycerol-3-Phosphate Acyltransferase-2 Is Expressed in Spermatic Germ Cells and Incorporates Arachidonic Acid into Triacylglycerols. *PLoS One* 2012; 7(8):e42986.

Target Protein	Product Name	Product Number	Validated Applications
Granulin	Anti-GRN	HPA008763[76]	IHC*,ICC-IF
Granulin	Anti-GRN	HPA028747[76]	IHC,ICC-IF
GSTP1	Anti-GSTP1	HPA019869[77]	IHC*,WB*,ICC-IF
HIF-1 alpha/HIF1A	Anti-HIF1A	HPA001275[78-81]	IHC
HJURP	Anti-HJURP	HPA008436[82-85]	IHC,ICC-IF
HMGCL	Anti-HMGCL	HPA004727[2]	IHC*,WB
HMGCR	Anti-HMGCR	HPA008338[86-88]	IHC
HMGCR	Anti-HMGCR	AMAb90619	IHC,WB*
HORMAD1/CT46	Anti-HORMAD1	HPA037850[89]	IHC*
HSD17B14	Anti-HSD17B14	HPA021467	IHC,WB*
IFI30	Anti-IFI30	HPA026650[90]	IHC,WB,ICC-IF
IL3RA	Anti-IL3RA	HPA003539[91]	IHC
KDM5B/CT31	Anti-KDM5B	HPA027179[92-95]	IHC*
KLK3/PSA	Anti-KLK3	HPA000764[96-98]	IHC
LSP1	Anti-LSP1	HPA019693[99]	IHC*,WB
MMP2	Anti-MMP2	HPA001939[45]	IHC,WB*
MRPS7	Anti-MRPS7	HPA022522[8]	IHC,WB,ICC-IF
MRPL40	Anti-MRPL40	HPA006181[8,102]	IHC,WB*,ICC-IF
MRPS15	Anti-MRPS15	HPA028134[8]	IHC*
MRPS22	Anti-MRPS22	HPA006083[8]	IHC*,WB*,ICC-IF
MSX2	Anti-MSX2	HPA005652[68,103,104]	IHC
MUC1/CA15-3	Anti-MUC1	HPA004179	IHC*
MUC1/CA15-3	Anti-MUC1	HPA007235	IHC
MUC1/CA15-3	Anti-MUC1	HPA008855[105]	IHC*
MX1/IFI-78K	Anti-MX1	HPA030917[106]	IHC,WB*
NBN	Anti-NBN	HPA001429	IHC,WB
NFATC2	Anti-NFATC2	HPA008789[107,108]	IHC*,WB,ICC-IF

* Products with enhanced validation for indicated application

HMGCR

(A) The Anti-HMGCR antibody (AMAb90619) shows moderate to strong cytoplasmic positivity in tumor cells in human breast cancer tissue samples using IHC. (B) By WB, HMGCR can be detected in MCF-7 and HepG2 cell lines.

76. Elkabets M *et al*. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. *J Clin Invest* 2011 Feb 1;121(2):784-99.

77. Ruckhäberle E *et al*. Breast Cancer Proteomics – Differences in Protein Expression between Estrogen Receptor-Positive and -Negative Tumors Identified by Tandem Mass Tag Technology. *Breast Care (Basel)* 2010 Mar; 5(1):7-10.

78. Zibert JR *et al*. Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions. *J Clin Invest* 2011 Jan 4;121(1):410-21.

79. Smyth LG *et al*. Carbonic anhydrase IX expression in prostate cancer. *Prostate Cancer and Prostatic Diseases* 2009 Dec;13(2):178-181.

80. Paatero I *et al*. Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling. *J Biol Chem* 2012 Mar 23;287(13):9659-71.

81. Zbytek B *et al*. Putative role of HIF transcriptional activity in melanocytes and melanoma biology. *Dermatoendocrinol* 2013 Apr 1; 5(2):239-251.

82. Hu Z *et al*. The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. *Breast Cancer Res* 2010;12(2):R18

83. Shuaib M *et al*. HJURP binds CENP-A via a highly conserved N-terminal domain and mediates its deposition at centromeres. *Proc Natl Acad Sci U S A* 2010 Jan 26;107(4):1349-54

84. de Tayrac M *et al*. Prognostic Significance of EDN/RB, HJURP, p60/CAF-1 and PDLI4, Four New Markers in High-Grade Gliomas. *PLoS One* 2013 Sep 11;8(9):e73332.

85. Huang W *et al*. A Non-Synonymous Single Nucleotide Polymorphism in the HJURP Gene Associated with Susceptibility to Hepatocellular Carcinoma among Chinese. *PLoS One* 2016 Feb; 11(2):e0148618.

86. Bjarnadottir O *et al*. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. *Breast Cancer Res Treat* 2013 Apr;138(2):499-508.

87. Bengtsson E *et al*. HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome. *Diagn Pathol* 2014 Apr 7; 9:78.

88. Gustbée E *et al*. Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients. *BMC Clin Pathol* 2015; 15:8.

89. Watkins J *et al*. Genomic complexity profiling reveals that HORMAD1 overexpression contributes to homologous recombination deficiency in triple-negative breast cancers. *Cancer Discov* 2015 May; 5(5):488-505.

90. Xiang YJ *et al*. Absence of Gamma-Interferon-Inducible Lysosomal Thiol Reductase (GILT) Is Associated with Poor Disease-Free Survival in Breast Cancer Patients. *PLoS One* 2014; 9(10):e109449. Epub 2014 Oct 21.

91. Mansfield AS *et al*. Metastasis to sentinel lymph nodes in breast cancer is associated with maturation arrest of dendritic cells and poor co-localization of dendritic cells and CD8+ T cells. *Virchows Arch* 2011 Oct; 459(4):391-8.

92. Yamamoto S *et al*. JARID1B is a luminal lineage-driving oncogene in breast cancer. *Cancer Cell* 2014 Jun 16; 25(6):762-777.

93. Zou MR *et al*. Histone Demethylase Jumonji AT-rich Interactive Domain 1B (JARID1B) Controls Mammary Gland Development by Regulating Key Developmental and Lineage Specification Genes. *J Biol Chem* 2014 Jun 20; 289(25):17620-17633.

94. Wang L *et al*. Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer. *Tumour Biol* 2015 Apr; 36(4):2465-2472.

95. Hayami S *et al*. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathwayVMol Cancer 2010 Mar 13; 9:59.

96. Jaraj SJ *et al*. GAD1 is a biomarker for benign and malignant prostatic tissue. *Scand J Urol Nephrol* 2011 Feb;45(1):39-45.

97. Liu H *et al*. Single-cell clones of liver cancer stem cells have the potential of differentiating into different types of tumor cells. *Cell Death Dis* 2013 Oct; 4(10):e857-.

98. Goto Y *et al*. MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker. *British Journal of Cancer* September 01, 2015.

99. Johansson J *et al*. TGF-β1-Induced Epithelial–Mesenchymal Transition Promotes Monocyte/Macrophage Properties in Breast Cancer Cells. *Front Oncol* 2015; 5:3.

100. Sohet F *et al*. LSR/angulin-1 is a tricellular tight junction protein involved in blood–brain barrier formation. *J Cell Biol* 2015 Mar 16; 208(6):703-711.

101. Reaves DK *et al*. The Role of Lipolysis Stimulated Lipoprotein Receptor in Breast Cancer and Directing Breast Cancer Cell Behavior. *PLoS One* 2014; 9(3):e91747.

102. Tappenden DM *et al*. The Aryl-Hydrocarbon Receptor Protein Interaction Network (AHR-PIN) as Identified by Tandem Affinity Purification (TAP) and Mass Spectrometry. *J Toxicol* 2013; 2013:279829.

103. Wirrig EE *et al*. Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves. *J Mol Cell Cardiol* 2011 Mar; 50(3):561-569.

104. Wensman H *et al*. Extensive expression of craniofacial related homeobox genes in canine mammary sarcomas. *Breast Cancer Res Treat* 2009 Nov; 118(2):333-43.

105. Lawson DA *et al*. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. *Nature* 2015 Oct 1; 526(7571):131-135.

106. Johansson HJ *et al*. Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. *Clin Proteomics* 2015; 12(1):8.

107. Scanlon CS *et al*. Galanin modulates the neural niche to favour perineural invasion in head and neck cancer. *Nat Commun* 2015 Apr 28; 6:6885.

108. Tran Quang C *et al*. The calcineurin/NFAT pathway is activated in diagnostic breast cancer cases and is essential to survival and metastasis of mammary cancer cells. *Cell Death Dis* 2015 Feb 26; 6(2):e1658-.

Target Protein	Product Name	Product Number	Validated Applications
NRF1	Anti-NRF1	HPA029329[8]	IHC,WB*,ICC-IF
NRP1	Anti-NRP1	HPA030278[111]	IHC
OGFOD1	Anti-OGFOD1	HPA003215[25,112-114]	IHC,WB,ICC-IF
P53	Anti-P53	AMAb90956[116]	IHC*,WB*,ICC-IF
Peroxiredoxin-1	Anti-PRDX1	HPA007730[117-119]	IHC,WB*,ICC-IF
PHGDH	Anti-PHGDH	HPA021241[120-123]	IHC,WB*,ICC-IF
PHGDH	Anti-PHGDH	AMAb90786	IHC,WB,ICC-IF
PGD	Anti-PGD	HPA031314	IHC*,WB
PIP/GCDFP	Anti-PIP	HPA009177	IHC,WB
Pirin	Anti-PIR	HPA000697[70]	IHC*,WB,ICC-IF
PKC alpha/PKCA	Anti-PKCA	HPA006563	IHC,WB*,ICC-IF
PKC alpha/PKCA	Anti-PKCA	HPA006564	IHC*,WB*,ICC-IF
PLAT	Anti-PLAT	HPA003412	IHC
POLRMT	Anti-POLRMT	HPA006366[8,124]	IHC,ICC-IF
PPP4R1	Anti-PPP4R1	HPA041089[125,126]	IHC,WB*
PSMC3IP	Anti-PSMC3IP	HPA044439[127]	IHC,WB*
PSMC4/TBP-7	Anti-PSMC4	HPA002044[128]	IHC,WB,ICC-IF
PSPH	Anti-PSPH	HPA020376[129,130]	IHC,WB*
PTMA	Anti-PTMA	HPA047183	IHC,ICC-IF
PTTG1	Anti-PTTG1	HPA008890	IHC
RAP80/UIMC1	Anti-UIMC1	HPA037503	IHC*,WB*,ICC-IF
RAP80/UIMC1	Anti-UIMC1	HPA037504	IHC*,WB,ICC-IF
RBM3	Anti-RBM3	HPA003624[131-132,14]	IHC,WB*,ICC-IF
RBM3	Anti-RBM3	AMAb90655[133-136]	IHC*,WB*,ICC-IF

* Products with enhanced validation for indicated application

PHGDH

(A) IHC staining of human cervix using Anti-PHGDH (HPA021241) antibody shows cytoplasmic and nuclear positivity in squamous epithelia. **(B)** By Western Blot analysis, PHGDH is detected in the human cell lines RT-4 and U-251MG. **(C)** ICC-IF in the human cell line U-2 OS shows positivity in plasma membrane & cytoplasm (in green).

P53

(A) IHC staining of human colorectal cancer using Anti-P53 (AMAb90956) antibody shows strong nuclear immunoreactivity in tumor cells. **(B)** By Western Blot analysis, P53 is detected in the human cell line U-251. **(C)** ICC-IF in the human cell line U-251 shows cell cycle dependent nuclear staining in green.

109. Yoo NJ et al. Expression of NRF2, a cytoprotective protein, in gastric carcinomas. APMIS 2010 Aug; 118(8):613-4.

110. Suchocki P et al. Selenitetriglicerydes affect CYP1A1 and QR activity by involvement of reactive oxygen species and Nrf2 transcription factor. Pharmacol Rep 2010 Mar-Apr; 62(2):352-61.

111. Venkova K et al. Semaphorin 3A Signaling Through Neuropilin-1 Is an Early Trigger for Distal Axonopathy in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. J Neuropathol Exp Neurol 2014 Jul; 73(7):702-713.

112. Kim JH et al. OGFOD1 is required for breast cancer cell proliferation and is associated with poor prognosis in breast cancer. Oncotarget 2015 Aug 14; 6(23):19528-19541.

113. Loenarz C et al. Hydroxylation of the eukaryotic ribosomal decoding center affects translational accuracy. Proc Natl Acad Sci U S A 2014 Mar 18; 111(11):4019-4024.

114. Wehner KA et al. OGFOD1, a novel modulator of eukaryotic translation initiation factor 2alpha phosphorylation and the cellular response to stress. Mol Cell Biol 2010 Apr; 30(8):2006-16.

115. Guo L et al. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene 2013 Nov 7;32(45):5272-82.

116. Hedström E et al. Downregulation of the cancer susceptibility protein WRAP53β in epithelial ovarian cancer leads to defective DNA repair and poor clinical outcome. Cell Death Dis 2015 Oct 1; 6(10):e1892-.

117. O'Leary PC et al. Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer. Breast Cancer Res 2014 Jul 10; 16(4):R79.

118. Kamper P et al. Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood 2011 Jun 16; 117(24):6638-49.

119. Dammeyer P and Arnér ES. Human Protein Atlas of redox systems - what can be learnt?. Biochim Biophys Acta 2011 Jan; 1810(1):111-38.

120. Possemato R et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011 Aug 18;476(7360):346-50.

121. Maddocks OD et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 2013 Jan 24;493(7433):542-6.

122. Pacold ME et al. A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nature Chemical Biology 2013 April 25, 2016.

123. DeNicola GM et al. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet 2015/12/01; 47(12):1475-1481.

124. Salem AF et al. Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. Cell Cycle 2012 Nov 15; 11(22):4174-4180.

125. Wu G et al. PP4R1 accelerates cell growth and proliferation in HepG2 hepatocellular carcinoma. Onco Targets Ther 2015; 8:2067-2074.

126. Qi Y et al. Lentivirus-Mediated Short-Hairpin RNA Targeting Protein Phosphatase 4 Regulatory Subunit 1 Inhibits Growth in Breast Cancer. J Breast Cancer 2015 Sep; 18(3):218-224.

127. Capdevila-Busquets E et al. Breast Cancer Genes PSMC3IP and EPSTI1 Play a Role in Apoptosis Regulation. PLoS One 2015; 10(1):e0115352.

128. Chen Y et al. Differential expression of novel tyrosine kinase substrates during breast cancer development. Mol Cell Proteomics 2007 Dec; 6(12):2072-87.

129. Krall AS et al. Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nat Commun 2016 Apr 29; 7:11457.

130. Possemato R et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011 Aug 18; 476(7360):346-50.

131. Jögi A et al. Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Mod Pathol 2009 Dec;22(12):1564-74.

132. Hjelm B et al. High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer. Proteomics Clin Appl 2011 Dec;5(11-12):624-35

133. Ehlén A et al. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med 2010 Aug 20;8:78

134. Nodin B et al. High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma. Diagn Pathol 2012 Jul 17;7:82.

135. Florianova L et al. Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study. World J Surg Oncol 2015 Nov 14; 13(None):317.

136. Olofsson SE et al. Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer. PLoS One 2015; 10(3):e0121300.

Target Protein	Product Name	Product Number	Validated Applications
RBM47	Anti-RBM47	HPA006347[137]	IHC*,WB*,ICC-IF
RRBP1	Anti-RRBP1	HPA009026[138]	IHC*,WB*,ICC-IF
RUNX1	Anti-RUNX1	HPA004176[139]	IHC*,ICC-IF
RUNX2	Anti-RUNX2	HPA022040[140-142]	IHC*,WB*,ICC-IF
SAGE1	Anti-SAGE1	HPA003208[143]	IHC*,ICC-IF
SATB2	Anti-SATB2	HPA001042[104,14,144,145]	IHC*,WB
SATB2	Anti-SATB2	AMAb90679	IHC,WB,ICC-IF
Septin-11	Anti-SEPT11	HPA003459[146]	IHC,WB
Septin-2	Anti-SEPT2	HPA018481[146,147]	IHC,WB*,ICC-IF
SIX1	Anti-SIX1	HPA001893[148-151]	IHC*,WB*,ICC-IF
SIX1	Anti-SIX1	AMAb90544	IHC,WB*,ICC-IF
SNCG	Anti-SNCG	HPA014404	IHC*,WB
STK11	Anti-STK11	HPA017254[152]	IHC
SURVIvin/BIRC5	Anti-BIRC5	HPA002830	IHC*,WB*
T-STAR/KHDRBS3	Anti-KHDRBS3	HPA000500[145,153]	IHC,WB

* Products with enhanced validation for indicated application

SIX1

(A) IHC staining using the Anti-SIX1 antibody (HPA001893) in human skeletal muscle tissue shows nuclear positivity in myocytes. (B) ICC-IF staining in U-251 cell line shows positivity in nucleus (in green).

RUNX1

(A) IHC staining of human bone marrow using Anti-RUNX1 (HPA004176) antibody shows strong nuclear positivity in bone marrow poietic cells. (B) ICC-IF in the human cell line A-431 shows positivity in nucleus and vesicles (in green).

SEPT2

(A) The Anti-SEPT2 antibody (HPA018481) shows distinct cytoplasmic positivity in astrocytes and endothelial cells in cerebral cortex, using IHC. (B) By ICC-IF in cell line U-2 OS, positivity in nucleus, nucleoli & actin filaments is shown.

SATB2

(A) The Anti-SATB2 antibody (AMAb90679) shows strong nuclear reactivity in glandular cells in human rectum tissue using IHC. (BV) By WB, SATB2 can be detected in the human cell line HEL.

137. Vanharanta S *et al*. Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer. *eLife* 2014 Jun 4; 3:e02734.

138. Telikicherla D *et al*. Overexpression of ribosome binding protein 1 (RRBP1) in breast cancer. *Clin Proteomics* 9(1):7.

139. Ferrari N *et al*. Expression of RUNX1 Correlates with Poor Patient Prognosis in Triple Negative Breast Cancer. *PLoS One* 2014; 9(6):e100759.

140. McDonald L *et al*. RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland. *Dis Model Mech* 2014 May; 7(5):525-534.

141. Ferrari N *et al*. Runx2 contributes to the regenerative potential of the mammary epithelium. *Sci Rep* 2015 Oct 22; 5:15658.

142. Martínez-Abadías N *et al*. From shape to cells: mouse models reveal mechanisms altering palate development in Apert syndrome. *Dis Model Mech* 2013 May; 6(3):768-779.

143. Maheswaran E *et al*. Lack of ADAM2, CALR3 and SAGE1 Cancer/Testis Antigen Expression in Lung and Breast Cancer. *PLoS One* 2015; 10(8):e0134967. .

144. Magnusson K *et al*. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. *Am J Surg Pathol* 2011 Jul; 35(7):937-48.

145. Ek S *et al*. From gene expression analysis to tissue microarrays: a rational approach to identify therapeutic and diagnostic targets in lymphoid malignancies. *Mol Cell Proteomics* 2006 Jun; 5(6):1072-81.

146. Froidevaux-Klipfel L *et al*. Modulation of septin and molecular motor recruitment in the microtubule environment of the Taxol-resistant human breast cancer cell line MDA-MB-231. *Proteomics* 2011 Oct; 11(19):3877-86.

147. Volceanov L *et al*. Septins Arrange F-Actin-Containing Fibers on the Chlamydia trachomatis Inclusion and Are Required for Normal Release of the Inclusion by Extrusion. *mBio* 2014 Oct 7; 5(5):e01802-14.

148. Iwanaga R *et al*. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. *Breast Cancer Res* 2012 Jul 5;14(4):R100.

149. Smith AL *et al*. The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. *Oncogene* 2012 Jan 30;

150. Christina G *et al*. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. *Nature Communications* 2015 Dec 21;6:10077.

151. Ono H *et al*. SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation. *Oncogene* 2012 Nov 22;31(47):4923-34.

152. Co NN *et al*. Loss of LKB1 in High Grade Endometrial Carcinoma: LKB1 is a Novel Transcriptional Target of p53. *Cancer* 2014 Nov 15; 120(22):3457-3468.

153. Sernbo S *et al*. Nuclear T-STAR Protein Expression Correlates with HER2 Status, Hormone Receptor Negativity and Prolonged Recurrence Free Survival in Primary Breast Cancer and Decreased Cancer Cell Growth In Vitro. *PLoS One* 2013; 8(7):e70596.

Target Protein	Product Name	Product Number	Validated Applications
Tenascin C/TNC	Anti-TNC	HPA004823[154-157]	IHC
TFAM/TCF-6	Anti-TFAM	HPA040648[8]	IHC,WB*,ICC-IF
TFF1	Anti-TFF1	HPA003425[158-160]	IHC*,WB*
THBD	Anti-THBD	HPA002982	IHC,WB,ICC-IF
THEM2/ACOT13	Anti-ACOT13	HPA019881	IHC,WB,ICC-IF
TIMM9	Anti-TIMM9	HPA002932[8]	IHC,ICC-IF
TOMM70	Anti-TOMM70A	HPA014589[8]	IHC*,WB,ICC-IF
TOP2A	Anti-TOP2A	HPA006458[161,162]	IHC*,WB
TOP2A	Anti-TOP2A	HPA026773	IHC*
UGT8	Anti-UGT8	HPA014405[163]	IHC
ULBP1	Anti-ULBP1	HPA007547[164-166]	IHC*
VRK1	Anti-VRK1	HPA000660[167-170]	IHC*,WB*,ICC-IF
WIPF2	Anti-WIPF2	HPA024467[171-174]	IHC*,WB*
WIPI1	Anti-WIPI1	HPA007493[175]	IHC*,WB*
ZEB1	Anti-ZEB1	HPA027524[176-179]	IHC*,ICC-IF
ZEB1	Anti-ZEB1	AMAb90510[180,181]	IHC,WB*,ICC-IF
ZEB2	Anti-ZEB2	HPA003456[104,182-184]	IHC,WB*
ZNF703	Anti-ZNF703	HPA023930[185]	IHC
ZNF703	Anti-ZNF703	AMAb90510	IHC,WB*,ICC-IF

* Products with enhanced validation for indicated application

154. Xu Y *et al*. The co-expression of MMP-9 and Tenascin-C is significantly associated with the progression and prognosis of pancreatic cancer. *Diagn Pathol*, 2015/12/10; 10:211.

155. Ghosh Z *et al*. Dissecting the Oncogenic Potential of Human Embryonic and Induced Pluripotent Stem Cell Derivatives. *Cancer Res* 2011 Jul 15; 71(14):5030-5039.

156. Bohonowych J *et al*. Extracellular Hsp90 mediates an NF-κB dependent inflammatory stromal program: Implications for the prostate tumor microenvironment. *Prostate*, 2014 Apr; 74(4):395-407.

157. Edlund K *et al*. CD99 is a novel prognostic stromal marker in non-small cell lung cancer. *Int J Cancer* 2012 Nov 15;131(10):2264-73.

158. Davidson B *et al*. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. *J Cell Mol Med* 2011 Mar;15(3):535-44.

159. Pontén F *et al*. The Human Protein Atlas--a tool for pathology. *J Pathol* 2008 Dec;216(4):387-93.

160. Wu CC *et al*. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. *Mol Cell Proteomics* 2010 Jun;9(6):1100-17.

161. Lindén M *et al*. Tumour expression of bladder cancer-associated urinary proteins. *BJU Int* 2013 Aug; 112(3):407-15.

162. Andersson S *et al*. Antibodies Biotinylated Using a Synthetic Z-domain from Protein A Provide Stringent In Situ Protein Detection. *J Histochem Cytochem* 2013 Nov; 61(11):773-784.

163. Dziegiel P *et al*. Ceramide galactosyltransferase (UGT8) is a molecular marker of breast cancer malignancy and lung metastases. *Br J Cancer* 2010 Aug 10;103(4):524-31.

164. Boerman GH *et al*. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells. *Cancer Immunol Immunother* 2015 May; 64(5):573-583.

165. Cho H *et al*. MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer. *BMC Cancer* 2014 Dec 15; 14:957.

166. de Kruijf EM *et al*. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. *BMC Cancer* 1224.

167. Salzano M *et al*. Vaccinia-related kinase 1 (VRK1) confers resistance to DNA-damaging agents in human breast cancer by affecting DNA damage response. *Oncotarget* 2014 Apr 15; 5(7):1770-1778.

168. Kim IJ *et al*. Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. *Nat Commun* 2013; 4:1701.

169. Molitor TP *et al*. Molecular genetic analysis of VRK in mammary epithelial cells: depletion slows proliferation in vitro and tumor growth and metastasis in vivo. *Oncogenesis* 2013 Jun 3; 2(6):e48-.

170. Cantarero L *et al*. VRK1 regulates Cajal body dynamics and protects coilin from proteasomal degradation in cell cycle. *Sci Rep* 2015 Jun 12; 5:10543.

171. García E *et al*. WIP and WICH/WIRE co-ordinately control invadopodium formation and maturation in human breast cancer cell invasion. *Sci Rep* 2016 Mar 24; 6:23590.

172. Wu SK *et al*. Active contractility at E-cadherin junctions and its implications for cell extrusion in cancer. *Cell Cycle* 2015; 14(3):315-322.

173. Wu SK *et al*. Cortical F-actin stabilization generates apical-lateral patterns of junctional contractility that integrate cells into epithelia. *Nat Cell Biol* 2014 Feb; 16(2):167-78.

174. Kovacs EM *et al*. N-WASP regulates the epithelial junctional actin cytoskeleton through a non-canonical post-nucleation pathway. *Nat Cell Biol* 2011 Jul 24; 13(8):934-43.

175. Felzen V *et al*. Estrogen receptor α regulates non-canonical autophagy that provides stress resistance to neuroblastoma and breast cancer cells and involves BAG3 function. *Cell Death Dis* 2015 Jul 9; 6(7):e1812-.

176. Werner S *et al*. Dual Roles of the Transcription Factor Grainyhead-like 2 (GRHL2) in Breast Cancer. *J Biol Chem* 2013 Aug 9; 288(32):22993-23008.

177. Jakobsen KR *et al*. Direct RNA sequencing mediated identification of mRNA localized in protrusions of human MDA-MB-231 metastatic breast cancer cells. *J Mol Signal* 2013 Sep 1; 8:9.

178. Lehmann W *et al*. ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. *Nat Commun* 2016 Feb; 7:10498.

179. De Sousa E Melo F *et al*. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. *Nat Med* 2013 May; 19(5):614-8.

180. Müller S *et al*. Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. *Mol Cancer* 2015 Apr 25; 14:94.

181. Varma S *et al*. Grainyhead-like 2 (GRHL2) distribution reveals novel pathophysiological differences between human idiopathic pulmonary fibrosis and mouse models of pulmonary fibrosis. *Am J Physiol Lung Cell Mol Physiol* 2014 Mar 1; 306(5):L405-L419.

182. Denecker G *et al*. Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. *Cell Death Differ* 2014 Aug; 21(8):1250-1261.

183. Fang Y *et al*. Protein Expression of ZEB2 in Renal Cell Carcinoma and Its Prognostic Significance in Patient Survival. *PLoS One* 2013; 8(5):e62558.

184. Cai MY *et al*. Overexpression of ZEB2 in Peritumoral Liver Tissue Correlates with Favorable Survival after Curative Resection of Hepatocellular Carcinoma. *PLoS One* 2012; 7(2):e32838.

185. Holland DG *et al*. ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. *EMBO Mol Med* 2011 Mar; 3(3):167-80.

ZEB1

(A) IHC staining of human cerebral cortex using Anti-ZEB1 (HPA027524) antibody shows strong nuclear positivity in glial cells. (B) By Western Blot analysis, ZEB1 is detected in the human cell line U-251. (C) ICC-IF in the human cell line U-2 OS shows positivity in nucleus, but excluded from the nucleoli (in green).

Antibodies against gene products in MammaPrint, Oncotype, EndoPredict and uPA tests

This section presents antibodies in Atlas Antibodies´ product catalog against gene products included in the diagnostic MammaPrint, EndoPredict, Oncotype and uPA tests. MammaPrint is a gene expression profile test based on the Amsterdam 70-gene breast cancer gene signature marketed by Agendia. It is a test to assess the risk that a breast tumor will metastasize to other parts of the body. MammaPrint aims at stratifying patients into "Low Risk" and "High Risk". Oncotype DX (developed by Genomic Health) is the most frequently used gene expression profile in clinical practice in the United States analyzing a panel of 21 genes within a tumor to determine a Recurrence Score.

| Target Protein	Product Name	Product Number	Validated Applications
AURKA/STK15	Anti-AURKA	HPA002636	IHC,WB,ICC-IF
AZGP1	Anti-AZGP1	HPA012582	IHC*,WB
BAG1	Anti-BAG1	HPA018121	IHC*
BIRC5/Survivin	Anti-BIRC5	HPA002830	IHC*,WB*
CD68/Macrosialin	Anti-CD68	HPA048982[1]	IHC,WB*
CD68/Macrosialin	Anti-CD68	AMAb90874	IHC,WB*
CDCA7	Anti-CDCA7	HPA005565[2,3]	ICC-IF
CMC2/C16orf61	Anti-CMC2	HPA006871	IHC
DHCR7	Anti-DHCR7	HPA044280	IHC,ICC-IF
DHX58/LGP2	Anti-DHX58	HPA018670	IHC,WB
DHX58/LGP2	Anti-DHX58	HPA019570	IHC
DTL	Anti-DTL	HPA028016[4]	IHC,WB
ECI2/PECI	Anti-ECI2	HPA022130	IHC*,WB*,ICC-IF
ECI2/PECI	Anti-ECI2	HPA031626	IHC*,WB*,ICC-IF
EGLN1/PHD2	Anti-EGLN1	HPA022129[5]	IHC,ICC-IF
Estrogen receptor	Anti-ESR1	AMAb90867	IHC,WB*,ICC-IF
Estrogen receptor	Anti-ESR1	HPA000449[6]	IHC*,WB*,ICC-IF
Estrogen receptor	Anti-ESR1	HPA000450[6]	IHC*,WB*
Exostosin-1	Anti-EXT1	HPA044394[7]	IHC
GNAZ	Anti-GNAZ	HPA003011	IHC*,WB*,ICC-IF
GPR126/VIGR	Anti-GPR126	HPA017346	IHC
GPR180	Anti-GPR180	HPA047250	IHC,ICC-IF
GSTM3	Anti-GSTM3	HPA035190	IHC*,WB
GSTM5/GSTM1	Anti-GSTM5	HPA048652	IHC,WB
HER2/ERBB2	Anti-HER2	AMAb90627	IHC,WB
HER2/ERBB2	Anti-HER2	AMAb90628	IHC,WB,ICC-IF

* Products with enhanced validation for indicated application

BIRC5/Survivin

The Anti- BIRC5 antibody (HPA002830) shows nuclear positivity in germinal center cells in human tonsil tissue **(A)** and in tumor cells in colorectal cancer **(B)** using IHC.

CD68/Macrosialin

IHC staining of human lung tissue using the Anti-CD68 antibody (HPA048982) shows strong cytoplasmic positivity in macrophages **(A)** and in hematopoietic tissues, such as spleen **(B)**.

DTL

(A) IHC staining of human bone marrow using the Anti-DTL antibody (HPA028016) shows strong nuclear positivity in bone marrow poietic cells. **(B)** By ICC-IF, staining of nucleus in U-251 MG cells is detected.

GSTM5

(A) The Anti-GSTM5 antibody (HPA048652) shows cytoplasmic positivity in glandular cells in human rectum by IHC. **(B)** In WB, the antibody detects a band of predicted size in cell lysates of RT-4, U-251 MG, as well as in liver tissue lysate.

1. Louveau A et al. Structural and functional features of central nervous system lymphatic vessels. Nature June 01, 2015.

2. Gill RM et al. The MYC-Associated Protein CDCA7 Is Phosphorylated by AKT To Regulate MYC-Dependent Apoptosis and Transformation. Mol Cell Biol 2013 Feb; 33(3):498-513.

3. Shubbar E et al. Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. BMC Cancer 131.

4. Karaayvaz M et al. Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer 2011 Dec;10(4):340-7.

5. Bozóky B et al. Novel signatures of cancer-associated fibroblasts. Int J Cancer 2013 Jul 15; 133(2):286-93.

6. Algenäs C et al. Antibody performance in western blot applications is context-dependent. Biotechnol J 2014 Mar; 9(3):435-45.

7. Coulson-Thomas VJ et al. Heparan Sulfate Regulates Hair Follicle and Sebaceous Gland Morphogenesis and Homeostasis. J Biol Chem 2014 Sep 5; 289(36):25211-25226.

Target Protein	Product Name	Product Number	Validated Applications
HER2/ERBB2	Anti-ERBB2	HPA001383[8,9]	IHC,WB,ICC-IF
HRASLS	Anti-HRASLS	HPA051179	IHC,ICC-IF
IL6ST/GP130	Anti-IL6ST	HPA010558[10]	IHC
JHDM1D/KDM7A	Anti-JHDM1D	HPA012114	IHC,ICC-IF
Ki67/MKI67	Anti-MKI67	HPA000451[11,12]	IHC*,ICC-IF
KI67/MKI67	Anti-MKI67	HPA001164[13]	IHC*,ICC-IF
KI67/MKI67	Anti-MKI67	AMAb90870	IHC,ICC-IF
LIN9	Anti-LIN9	HPA030241	IHC,ICC-IF
LPCAT/AYTL2	Anti-LPCAT1	HPA012501	IHC*,WB
LPCAT/AYTL2	Anti-LPCAT1	HPA022268[14,15]	IHC*,WB*
LYRIC/MTDH	Anti-MTDH	HPA015104[16,17]	IHC,WB*,ICC-IF
LYRIC/MTDH	Anti-MTDH	HPA010932[18]	IHC,WB*,ICC-IF
LYRIC/MTDH	Anti-MTDH	AMAb90762	IHC,WB,ICC-IF
LYRIC/MTDH	Anti-MTDH	AMAb90763	IHC,WB,ICC-IF
Matrix Gla protein	Anti-MGP	HPA013949[19]	IHC
MCM6	Anti-MCM6	HPA004818	IHC*,WB*,ICC-IF
MELK/PK38	Anti-MELK	HPA017214	IHC,WB*
MMP9	Anti-MMP9	HPA001238[20,21]	IHC*,ICC-IF
MMP9	Anti-MMP9	AMAb90804	IHC,WB
MMP9	Anti-MMP9	AMAb90805	IHC,WB
MMP9	Anti-MMP9	AMAb90806	IHC
MS4A7	Anti-MS4A7	HPA017418	IHC,WB

* Products with enhanced validation for indicated application

8. Huvila J *et al*. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. *Gynecol Oncol* 2013 Sep; 130(3):463-9.

9. Newie I *et al*. The HER2-Encoded miR-4728-3p Regulates ESR1 through a Non-Canonical Internal Seed Interaction. *PLoS One* 2014; 9(5):e97200.

10. Rognum IJ *et al*. Interleukin-6 and the serotonergic system of the medulla oblongata in the sudden infant death syndrome. *Acta Neuropathol 2009* Oct;118(4):519-3.

11. Pohler E *et al*. Haploinsufficiency for AAGAB causes clinically heterogeneous forms of punctate palmoplantar keratoderma. *Nat Genet* 2012 Oct 14;44(11):1272-6.

12. Li S *et al*. Endothelial VEGF Sculpts Cortical Cytoarchitecture. *J Neurosci* 2013 Sep 11; 33(37):14809-14815.

13. Roca H *et al*. IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin upregulation. *J Cell Biochem* 2012 May; 113(5):1569-1580.

14. Friedman JS *et al*. Loss of lysophosphatidylcholine acyltransferase 1 leads to photoreceptor degeneration in rd11 mice. *Proc Natl Acad Sci U S A* 2010 Aug 31;107(35):15523-8.

15. Dai X *et al*. AAV-Mediated Lysophosphatidylcholine Acyltransferase 1 (Lpcat1) Gene Replacement Therapy Rescues Retinal Degeneration in rd11 Mice. *Invest Ophthalmol Vis Sci* 2014 Mar 20; 55(3):1724-1734.

16. Nohata N *et al*. Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). *J Hum Genet* 2011 Aug;56(8):595-601.

17. Giopanou I *et al*. Metadherin, p50, and p65 Expression in Epithelial Ovarian Neoplasms: An Immunohistochemical Study. *Biomed Res Int* 2014; 2014:178410.

18. Liu B *et al*. Astrocyte elevated gene-1 regulates osteosarcoma cell invasion and chemoresistance via endothelin-1/endothelin A receptor signaling.*Oncol Lett* 2013 Feb;5(2):505-510.

19. Lorenzen JM *et al*. Fetuin, matrix-Gla protein and osteopontin in calcification of renal allografts. *PLoS One* 2012;7(12):e52039.

20. Bass JA *et al*. Investigation of potential early Histologic markers of pediatric inflammatory bowel disease. *BMC Gastroenterol* 2015 Oct 13; 15:129.

21. Song C *et al*. Histone Deacetylase (HDAC) 10 Suppresses Cervical Cancer Metastasis through Inhibition of Matrix Metalloproteinase (MMP) 2 and 9 Expression. *J Biol Chem* 2013 Sep 27; 288(39):28021-28033.

MMP9

IHC staining of human lung tissue using the Anti-MMP9 antibody (HPA001238) shows strong nuclear positivity in macrophages **(A)** and in bone marrow poietic cells in bone marrow tissue **(B)**.

Monclonal Anti-MMP9 antibodies show strong cytoplasmic positivity in a subset of lymphoid cells in duodenum (AMAb90805) **(A)** and in human tonsil tissue (AMAb90804) **(B)**.

LYRIC/MTDH

(A) IHC staining using the Anti-MTDH antibody (HPA010932) shows strong cytoplasmic positivity in neuronal cells in human cerebral cortex tissue. **(B)** In ICC-IF in A-431 cell line, the antibody stains endoplasmic reticulum.

IHC staining using the monclonal Anti-MTDH antibody (AMAb90762) shows strong cytoplasmic reactivity in tumor cells from breast **(A)** and colorectal cancer samples **(B)**.

LPCAT1/AYTL2

(A) IHC staining of human lung using Anti-LPCAT1 (HPA022268) antibody shows strong cytoplasmic positivity in pneumocytes. **(B)** By Western Blot analysis, LPCAT1 is detected in the human cell lines RT-4 and U-251. **(C)** ICC-IF in the human cell line U-2 OS shows positivity in endoplasmic reticulum (in green).

Target Protein	Product Name	Product Number	Validated Applications
MYBL2	Anti-MYBL2	HPA030530	IHC
Neuromedin-U	Anti-NMU	HPA025926	IHC
NUSAP1	Anti-NUSAP1	HPA042904	IHC*,ICC-IF
P5C dehydrogenase	Anti-ALDH4A1	HPA006401	IHC*,WB
PITRM1/MP1	Anti-PITRM1	HPA006753	IHC*,WB*,ICC-IF
PITRM1/MP1	Anti-PITRM1	HPA006754	IHC*,WB*
PLAU/UPA	Anti-PLAU	HPA008719	IHC
PRC1	Anti-PRC1	HPA034521	IHC*,WB
Progesteron receptor	Anti-PGR	HPA004751[22]	IHC*
Progesteron receptor	Anti-PGR	HPA008428[23]	IHC*
Progesteron receptor	Anti-PGR	HPA017176	IHC*
QSOX2/QSCN6L1	Anti-QSOX2	HPA012716	IHC,ICC-IF
RBBP8	Anti-RBBP8	HPA039890	IHC
RECQL5	Anti-RECQL5	HPA029971[24]	IHC,WB*,ICC-IF
RTN4RL1/NgR3	Anti-RTN4RL1	HPA044428	IHC
RUNDC1	Anti-RUNDC1	HPA023726	IHC,WB,ICC-IF
SCUBE2/CEGP1	Anti-SCUBE2	HPA006353	IHC
SCUBE2/CEGP1	Anti-SCUBE2	HPA029871	IHC
SCOT/OXCT1	Anti-OXCT1	HPA012047[25]	IHC*,WB*,ICC-IF
SCOT/OXCT1	Anti-OXCT1	HPA061425	IHC*,ICC-IF
SERPINE1/PAI1	Anti-SERPINE1	HPA050039[26]	IHC,ICC-IF
SLC2A3/GLUT3	Anti-SLC2A3	HPA006539[27,28]	IHC,ICC-IF
Stanniocalcin-2	Anti-STC2	HPA045372	IHC, WB*,ICC-IF
TMEM74B/C20orf46	Anti-TMEM74B	HPA045213	IHC,ICC-IF
TSPYL5	Anti-TSPYL5	HPA031347	IHC*,ICC-IF
UCHL5	Anti-UCHL5	HPA005908	IHC
VEGFR-1	Anti-FLT1	AMAb90703	IHC*
VEGFR-1	Anti-FLT1	AMAb90704	IHC*,WB
WISP1	Anti-WISP1	HPA007121	ICC-IF

* Products with enhanced validation for indicated application

22. Pereira CB *et al.* Prognostic and Predictive Significance of MYC and KRAS Alterations in Breast Cancer from Women Treated with Neoadjuvant Chemotherapy. *PLoS One* 2013;8(3):e60576.

23. Huvila J *et al.* Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. *Gynecol Oncol* 2013 Sep; 130(3):463-9.

24. Lao VV *et al.* Altered RECQ Helicase Expression in Sporadic Primary Colorectal Cancers. *Transl Oncol.* 2013 Aug; 6(4):458-469.

25. Chang HT *et al.* Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet therapy. *Nutr Metab* (Lond) 1047.

26. Zhang G *et al.* Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature. *Diagn Pathol* 2014 Nov 12; 9:200.

27. Munthe S *et al.* Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype. *PLOS ONE* May 12, 2016.

28. Wang W *et al.* AMPK modulates Hippo pathway activity to regulate energy homeostasis. *Nat Cell Biol* 2015 Apr; 17(4):490-499.

PITRM1/MP1

(A) The Anti-PITRM1 antibody (HPA006753) shows strong cytoplasmic positivity in myocytes in human heart muscle using IHC. (B) ICC-IF staining of human cell line U-251 MG shows positivity in mitochondria.

PRC1

(A) IHC staining of human testis tissue using the Anti-PRC1 antibody (HPA034521) shows strong nuclear positivity in cells of seminiferus ducts. (B) ICC-IF shows staining of nucleus, plasma membrane and microtubules in A-431 cells.

SCOT/OXCT1

IHC staining of human heart muscle (A) and kidney (B) by Anti-OXCT1 antibody (HPA028016) shows strong cytoplasmic positivity in myocytes and cells in tubules, respectively. (C) ICC-IF shows staining of mitochondria in A431 cells.

P5C dehydrogenase/ALDH4A1

IHC staining using the Anti-ALDH4A1 antibody (HPA006401) shows strong cytoplasmic positivity with granular pattern in human kidney (A) and liver tissues (B).

Antibodies identified in the Human Protein Atlas

## - showing differential IHC staining patterns in breast cancer samples

Product Name	Product Number	Validated Applications
Anti-AAMDC	HPA037918	IHC*,WB*,ICC-IF
Anti-AAMDC	HPA037919	IHC*,ICC-IF
Anti-ACSF2	HPA024693	IHC*,WB,ICC-IF
Anti-ADAMTS13	HPA042014	IHC
Anti-ADIRF	HPA026810	IHC,ICC-IF
Anti-AGR3	HPA053942	IHC*,ICC-IF
Anti-AIF1L	HPA020522	IHC*
Anti-AJUBA	HPA006171[1]	IHC,WB,ICC-IF
Anti-ALDH1A3	HPA046271[2]	IHC*,WB*,ICC-IF
Anti-ANKRD46	HPA013758	IHC,WB*,ICC-IF
Anti-ASB6	HPA004341	IHC,WB
Anti-ATF6	HPA005935	IHC
Anti-ATP6V1B2	HPA008147	IHC*,WB*,ICC-IF
Anti-BCL9	HPA020274	IHC*,ICC-IF
Anti-C10orf54	HPA007968	IHC,WB*
Anti-C12orf76	HPA039713	IHC,WB*,ICC-IF
Anti-C17orf85	HPA008959[3]	IHC,ICC-IF
Anti-C2orf68	HPA051143	IHC,ICC-IF
Anti-CCDC170	HPA027185	IHC*,WB*
Anti-CDK6	HPA002637	IHC*,WB*,ICC-IF
Anti-CLDN3	HPA014361	IHC,ICC-IF
Anti-CPNE2	HPA041132	IHC,WB,ICC-IF
Anti-CRABP2	HPA004135[4]	IHC,WB*,ICC-IF
Anti-CTNND2	HPA015077	IHC*
Anti-CXorf67	HPA006128	IHC*,WB*,ICC-IF
Anti-CYP4X1	HPA017661	IHC,WB*
Anti-DACH1	HPA012672[5-7]	IHC,ICC-IF
Anti-DCHS1	HPA050246	IHC
Anti-DCLK1	HPA015655	IHC*,WB
Anti-DOM3Z	HPA046708	IHC,ICC-IF
Anti-ECD	HPA006465	IHC,WB,ICC-IF
Anti-EFHD1	HPA049331	IHC*,ICC-IF
Anti-EPHA6	HPA007397	IHC,WB*,ICC-IF
Anti-FAM189A1	HPA009410	IHC,ICC-IF
Anti-FKBP7	HPA008707	IHC,WB*,ICC-IF
Anti-GABRD	HPA044371	IHC*
Anti-GAK	HPA027463	IHC,ICC-IF

* Products with enhanced validation for indicated application

1. Tsuneki M *et al*. A hydrogel-endothelial cell implant mimics infantile hemangioma: modulation by survivin and the Hippo pathway. *Laboratory Investigation* 2015 95, 765–780.

2. Giraddi RR *et al*. Stem and progenitor cell division kinetics during postnatal mouse mammary gland development. *Nat Commun* 2015 Oct 29; 6:8487.

3. Gebhardt A *et al*. mRNA export through an additional cap-binding complex consisting of NCBP1 and NCBP3. *Nat Commun* 2015 Sep 18; 6:8192.

4. Seidensaal K *et al*. Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma. *Mol Cancer* 2015/12/03; 14:204.

5. Zhou J *et al*. DACH1, a Zona Glomerulosa Selective Gene in the Human Adrenal, Activates Transforming Growth Factor-β Signaling and Suppresses Aldosterone Secretion. *Hypertension* 2015 May; 65(5):1103-1110.

6. Powe DG *et al*. DACH1: Its Role as a Classifier of Long Term Good Prognosis in Luminal Breast Cancer. *PLoS One* 2014; 9(1):e84428.

7. Vonlanthen J *et al*. A comprehensive look at transcription factor gene expression changes in colorectal adenomas. *BMC Cancer* 2014 Jan 29; 14:46.


IHC analysis using Anti-KLHL26 antibody (HPA023074) shows a varying membranous/cytoplasmic staining pattern in breast tumor samples from different patients.

The Anti-ACSF2 (HPA024693) antibody shows granular cytoplasmic positivity in breast tumor cells from different patients varying from strong to negative.

The Anti-GCM1 (HPA011343) antibody shows membranous positivity in breast tumor cells (left) while normal breast tissue is negative (right).

The Anti-AGR3 (HPA053942) antibody shows strong cytoplasmic positivty in 3/4 breast cancer patients, while 1 patient is completely negative.

Product Name	Product Number	Validated Applications
Anti-GCM1	HPA011343[8]	IHC*,ICC-IF
Anti-GLDC	HPA002318[9]	IHC*,WB*
Anti-GLYATL1	HPA039501	IHC,WB
Anti-GTF3A	HPA007990	IHC,ICC-IF
Anti-HIPK2	HPA007611	IHC
Anti-HMGCS1	HPA036913	IHC,WB
Anti-HMGCS2	HPA027423	IHC*,WB*
Anti-HMGCS2	HPA027442	IHC*,WB*,ICC-IF
Anti-IFITM3	HPA004337	IHC,WB*
Anti-IRX2	HPA054669	IHC
Anti-ISYNA1	HPA007931	IHC*,WB,ICC-IF
Anti-ISYNA1	HPA008232	IHC*,WB
Anti-ITGA3	HPA008572	IHC*,WB*
Anti-ITGBL1	HPA005676	IHC
Anti-ITIH6	HPA000506	IHC
Anti-KLHL26	HPA023074	IHC,WB
Anti-KRT31	HPA049550	IHC
Anti-LASP1	HPA012072[10]	IHC*,WB,ICC-IF
Anti-LRRIQ4	HPA036706	IHC
Anti-MAGEB1	HPA002820	IHC*
Anti-MANSC4	HPA039454	IHC
Anti-MROH2B	HPA059457	IHC
Anti-MRS2	HPA017642	IHC,WB
Anti-MSTO1	HPA005914	IHC
Anti-MTMR2	HPA049831	IHC,ICC-IF
Anti-MYBBP1A	HPA005466	IHC*,WB,ICC-IF
Anti-NAPEPLD	HPA024338	IHC,WB,ICC-IF
Anti-NASP	HPA028136	IHC*,WB*,ICC-IF
Anti-NFIA	HPA006111[11]	IHC*,WB*,ICC-IF
Anti-NIM1	HPA007695	IHC
Anti-NKAIN1	HPA006873	IHC
Anti-NPSR1	HPA007489[12]	IHC
Anti-OR2Z1	HPA048760	IHC
Anti-OR9K2	HPA015808	IHC
Anti-OTOP2	HPA024524	IHC
Anti-PDE4C	HPA048975	IHC*
Anti-PEG10	HPA051038	IHC*,ICC-IF
Anti-PHLPP1	HPA020200	IHC
Anti-PHTF2	HPA012312	IHC,ICC-IF
Anti-PKN3	HPA045390	IHC
Anti-PNMA5	HPA044690	IHC*
Anti-PPP1R35	HPA051607	IHC*
Anti-PPR11	HPA023923[13,14]	IHC,WB*
Anti-PVALB	HPA048536	IHC*,WB,ICC-IF
Anti-RAB31	HPA019717[15]	IHC,WB*
Anti-RAC3	HPA047820	IHC,WB
Anti-RAD18	HPA008752	IHC,WB*,ICC-IF
Anti-REEP1	HPA058061	IHC*
Anti-RIOK2	HPA005681	IHC,ICC-IF
Anti-RPS13	HPA005985	IHC,ICC-IF
Anti-S100A1	HPA006462[16]	IHC*,WB
Anti-S100A13	HPA019592[17,18]	IHC,WB,ICC-IF
Anti-S100A14	HPA027613	IHC*,WB*,ICC-IF
Anti-S100A7	HPA006997	IHC
Anti-SGK196/POMK	HPA013321	IHC,WB*,ICC-IF
Anti-SH3BGRL	HPA051248	IHC,WB*,ICC-IF
Anti-SHROOM1	HPA037690	IHC

Product Name	Product Number	Validated Applications
Anti-SIMC1	HPA037889	ICC-IF
Anti-SLC16A7	HPA005911	IHC,WB*
Anti-SLC39A6	HPA042377	IHC
Anti-SPAG1	HPA023748	IHC,ICC-IF
Anti-SQLE	HPA018038[19]	IHC
Anti-SRPRB	HPA011173	IHC,ICC-IF
Anti-SSSCA1	HPA039789	IHC,WB,ICC-IF
Anti-STAG3	HPA049106	IHC*
Anti-STX7	HPA001467[20]	IHC*,WB,ICC-IF
Anti-TACC3	HPA005781[21]	IHC,WB*
Anti-TAPBP	HPA007066	IHC
Anti-TBC1D9	HPA000262	IHC
Anti-TGFBI	HPA017019	IHC*,WB
Anti-TMEM222	HPA016579	IHC
Anti-TMEM68	HPA018216	IHC
Anti-TPX2	HPA005487	IHC*,WB,ICC-IF
Anti-TTLL12	HPA003054	IHC,ICC-IF
Anti-UBE20	HPA023605	IHC,WB,ICC-IF
Anti-WFDC2	HPA042302	IHC*,WB,ICC-IF
Anti-ZBTB7B	HPA006811	IHC*,ICC-IF
Anti-ZKSCAN3	HPA009637	IHC
Anti-ZNF131	HPA007023	IHC
Anti-ZNF627	HPA049770	IHC,WB
Anti-ZNF662	HPA039116	IHC,WB

* Products with enhanced validation for indicated application

8. Renaud SJ *et al*. OVO-like 1 regulates progenitor cell fate in human trophoblast development. *Proc Natl Acad Sci U S A* 2015/11/10; 112(45):E6175-E6184.

9. Kim D *et al*. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. *Nature* April 08, 2015.

10. Ngan E *et al*. A complex containing LPP and α-Actinin mediates TGF β-induced migration and invasion of ErbB2-expressing breast cancer cells. *J Cell Sci* 2013 May 1; 126(0 9):1981-1991.

11. Nagao M *et al*. Zbtb20 promotes astrocytogenesis during neocortical development. *Nat Commun* 1/01/01; 7:11102.

12. Camilleri M *et al*. Neuropeptide S receptor induces neuropeptide expression and associates with intermediate phenotypes of functional gastrointestinal disorders. *Gastroenterology* 2010 Jan;138(1):98-107.e4.

13. Song Z *et al*. PRR11 Is a Prognostic Marker and Potential Oncogene in Patients with Gastric Cancer. *PLoS One* 2015; 10(8):e0128943.

14. Chen Y *et al*. The prognostic potential and oncogenic effects of PRR11 expression in hilar cholangiocarcinoma. *Oncotarget* 2015 Aug 21; 6(24):20419-20433.

15. Bozóky B *et al*. Novel signatures of cancer-associated fibroblasts. *Int J Cancer* 2013 Jan 15.

16. Peluffo H *et al*. CD300f immunoreceptor contributes to peripheral nerve regeneration by the modulation of macrophage inflammatory phenotype. *J Neuroinflammation* 2015 Aug 12; 12:145.

17. Dinets A *et al*. Differential Protein Expression Profiles of Cyst Fluid from Papillary Thyroid Carcinoma and Benign Thyroid Lesions. *JPLoS One* 2015; 10(5):e0126472.

18. Azimi A, *et al*. Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance. *Br J Cancer* 2014 May 13; 110(10):2489-2495.

19. Nguyen VT, *et al*. Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. *Nat Commun* 2015 Nov 27; 6:10044.

20. Strömberg S *et al*. Selective expression of Syntaxin-7 protein in benign melanocytes and malignant melanoma. *J Proteome Res* 2009 Apr;8(4):1639-46.

21. Guo Y *et al*. Regulating the ARNT/TACC3 axis: Multiple approaches to manipulating protein/protein interactions with small molecules. *JACS Chem Biol* 2013 Mar 15; 8(3):626-635.

Finding Cancer Biomarkers: RBM3, granulin and anillin

Breast Cancer

Breast cancer is the second most common cancer and by far the most frequent cancer among women. The incidence of breast cancer is increasing steadily, but without a corresponding increase in mortality. If detected at an early stage, the prognosis is relatively good for a patient living in a developed country, with a general five-year survival rate of approximately 85%.

Treatments

Cancer, though often denoted as a singular disease, is truly a multitude of diseases. This understanding has evolved over the years, but many patients are not receiving optimal treatment for their disease. For cancer patients to receive a more individualized treatment, there is still a need for new and better ways to stratify patients.

The classical prognostic factors such as stage and grade of the tumor are insufficient for a correct estimation of patient prognosis. Additional information from cancer biomarkers promise to substantially improve this estimation, ultimately leading to a more individualized treatment, thus avoiding both under- and over treatment of patients.

The primary curative treatment for breast cancer patients is surgery, often in combination with adjuvant therapy. However, adjuvant therapy is associated with substantial costs and sometimes severe side effects. Physicians have identified reduction of overtreatment as the major clinical need in breast cancer treatment today. Thus, the stratification of patients into different prognostic categories is of great importance as it may aid physicians in selecting the most appropriate treatment for a given patient.

The majority of breast cancers are hormone receptor responsive, i.e., express the estrogen receptor (ER) and/or the progesteron receptor (PR). Patients with tumors expressing these receptors may receive adjuvant endocrine treatment, such as tamoxifen.

Breast cancers may also express the HER2 protein (human epidermal growth factor receptor 2), and patients with tumors expressing this protein may receive adjuvant therapy with trastuzumab.

Adjuvant treatment may also consist of chemotherapy or radiation therapy.

RBM3

The RNA-binding motif protein 3 (RBM3) is an RNA- and DNA-binding protein, whose function has not been fully elucidated. It has been shown that the protein is expressed as an early event in mild hypothermia, and also in other conditions relating to cellular stress, such as glucose deprivation and hypoxia[1].

During stress, RBM3 is thought to protect the cells by aiding in maintenance of protein synthesis needed for survival[1]. Recently, it has also been shown that RBM3 attenuates stem cell-like properties in prostate cancer cells[2].

Through its differential expression pattern in several cancers types, RBM3 is now considered a potential oncology biomarker as reported in the Human Protein Atlas (HPA) project (proteinatlas.org)[3,4].

The IHC analysis using the Anti-RBM3 antibody HPA003624, showed a weak expression pattern in normal breast tissue, but a stratified pattern in breast cancer tissue (Figure 1).

Researchers further investigated the expression in larger breast cancer cohorts and the expression of RBM3 was shown to be associated with a prolonged survival[5].

A. Healthy tissue - weak

B. Cancer tissue - weak

C. Cancer tissue - strong

Figure 1.
IHC analysis using the Anti-RBM3 antibody (HPA003624) shows weak expression in normal healthy breast tissue (**A**) and differential expression, varying from weak to strong in tumor breast samples (**B, C**).

1. Ehlén Å (2011) PhD Thesis: The role of RNA-binding motif 3 in epithelial ovarian cancer: A biomarker discovery approach.

2. Zeng Y *et al*. (2013) Stress response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing. Cancer Res. May 10.

3. Berglund L *et al*. (2008) A gene-centric human protein atlas for expression profiles based on antibodies. Molecular & Cellular Proteomics 7:2019-2027.

4. Uhlén M *et al*. (2010) Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 28(12):1248-50.

RBM3 as a prognostic biomarker in breast cancer

After identification of RBM3 as a potential prognostic biomarker, researchers further investigated the RBM3 protein expression in larger breast cancer cohorts[5]. In a cohort of 500 premenopausal women with stage II invasive breast cancer, RBM3 expression was found to be associated with small, low-grade, estrogen receptor (ER)-positive tumors. When analyzing the subset of ER-positive patients, RBM3 was an independent predictor of recurrence free survival (RFS). As shown in Figure 2, patients with tumors expressing high levels of the RBM3 protein have an improved survival compared to patients with tumors expressing low levels of RBM3.

RBM3 protein expression has further been analyzed in many different patient cohorts from various forms of cancer. Levels of RBM3 expression was found to have a significant connection to patient survival in breast[5], colon[6], ovarian[7,8], testicular, urothelial[9], and prostate[10] cancer as well as in malignant melanoma[11].

In conclusion, RBM3 is a marker of good prognosis in breast cancer as well as in several other cancers.

RBM3 antibodies

There are two Anti-RBM3 antibodies in the Atlas Antibodies´ product catalog: the Triple A Polyclonal HPA003624 and the PrecisA Monoclonal AMAb90655.

The monoclonal Anti-RBM3 antibody shows excellent specificity in Western Blot analysis of human cell lines, and is routinely used for staining of formalin fixed paraffin embedded tissue in IHC (Figure 3.)

5. Jögi A *et al*. (2009) Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Mod Pathol. Dec;22(12):1564-74.

6. Hjelm B *et al*. (2011) High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer. Proteomics Clin Appl. Dec;5(11-12):624-35

7. Ehlén Å *et al* (2010) Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med. Aug 20; 8:78.

8. Ehlén Å *et al*. (2011) RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Transl Oncol. Aug;4(4):212-21.

9. Boman K *et al* (2013) Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer. BMC Urol. 2013;13:17

10. Jonsson L *et al. (*2011) High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression. Diagn Pathol. Sep 28;6:91.

11. Jonsson L *et al*. (2011) Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study. J Transl Med. Jul 21;9:114.

Figure 2
Kaplan-Meier (survival) analysis of recurrence free survival (RFS) according to RBM3 expression for ER-positive breast cancer patients. Patients were split into two groups based on high and low RBM3 expression.


Figure 3
Immunohistochemical analysis of RBM3 expression in breast cancer (left) and prostate cancer (right) using AMAb90655 shows nuclear positivity in tumor cells. The WB image shows the expected band of 17 kDa in human cell line RT4 lysate using AMAb90655.

Granulin

Granulins are a family of secreted, glycosylated peptides that are cleaved from a single precursor protein. Cleavage of the signal peptide produces mature granulin which can be further cleaved into a variety of active peptides. These cleavage products are named granulin A, granulin B, granulin C, etc. Both the peptides and intact granulin protein regulate cell growth.

Different members of the granulin protein family may act as inhibitors, stimulators, or have dual actions on cell growth. Granulin family members are important in normal development, wound healing, and tumorigenesis [provided by RefSeq, Jul 2008].

In a paper by Elkabets *et al*, the role of GRN expression in responding tumor instigation was investigated by studying recrution of GRN-expressing bone marrow cells into responding tumors in mice[1]. Certain tumors can foster the growth of other tumors or metastatic cells located at distant anatomical sites, which is referred to as tumor instigation.

In this study[1], rigorously growing human breast carcinoma cells were implanted in mice showing that these cells stimulated the outgrowth of otherwise poorly tumorigenic, indolent transformed cells. GRN was identified as the most upregulated gene in the instigating bone marrow cells.

The GRN expressing cells induced resident fibroblasts to express genes that promoted malignant tumor progression. It was speculated whether anticancer therapies might involve targeting GRN, or the activated GRN expressing cells, and thereby disrupting these cell lines of communication that promote cancer progression.

By using the Anti-GRN antibody HPA028747 in the analysis of tumor tissues from a cohort of breast cancer patients, high GRN expression was shown to correlate with the most aggressive triple-negative, basal-like tumor subtype and reduced patient survival (Figure 1).

Granulin antibodies

Atlas Antibodies' product catalog, lists two polyclonal Anti-GRN antibodies: HPA008763 and HPA028747.

1. Elkabets M *et al*. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. *J Clin Invest* 2011 Feb 1;121(2):784-99.

(A) IHC staining of human pancreas tissue using the Anti-GRN antibody (HPA008763) shows strong cytoplasmic positivity in exocrine glandular cells. **(B)** ICC-IF shows positivity in vesicles in A-431 cells.

IHC analysis using the Anti-GRN antibody HPA028747 shows strong cytoplasmic positivity in normal duodenum tissue in glanduclar cells **(A)** and vesicle positivity in U-251 MG cells **(B)**.

Figure 1
GRN expression correlates with aggressive tumor subtypes and reduced survival of breast cancer patients using antibody HPA028747. The diagram on the left shows percentage of tumors in each category (Triple-Negative [TN]/basal or nonbasal) displaying high GRN positivity. On the right, the Kaplan-Meier analysis shows correlation between GRN-positive (green) or GRN-negative (blue) expression and survival.

Anillin

Anillin is an actin binding protein that is a subunit of microfilaments, one of the cytoskeleton components. Anillin is expressed in most cells and is involved in basic cell functions, e.g. motility, division and signaling. Studies of anillin expression have shown that it is overexpressed in several human tumors.

Anillin as a treatment predictive prognostic biomarker in breast cancer

Anillin expression was analyzed in a patient cohort consisting of 467 samples from patients diagnosed with breast cancer, using the Anti-ANLN antibody HPA005680. Patients with tumors expressing high levels of anillin had a reduced recurrence free survival (RFS) compared to patients with tumors expressing low levels of anillin (Figure 1A). The same association between anillin expression and reduced survival could be seen when analyzing breast cancer specific survival (BCSS, Figure 1B).

In a study by O´Leary *et al*, the prognostic impact of anillin was confirmed by Cox regression analysis. High anillin expression was associated with reduced BCSS and RFS in univariate- as well as in multivariate analysis, adjusted for tumor size and grade, age at diagnosis, nodal-, ER-, PR-, HER2-, and Ki67 status.

In conclusion, anillin is a marker for poor prognosis in breast cancer.

Anillin antibodies

There are three Anti-ANLN antibodies in Atlas Antibodies product catalog; the PrecisA Monoclonals AMAb90660 and AMAb90662 and the Triple A Polyclonal HPA005680.

The Anti-ANLN antibody (HPA005680) shows strong nuclear positivity in cells in seminiferous ducts in human testis by IHC. In ICC-IF, nuclei (but not nucleoli) of A-431 cells stain positively and in WB, the antibody detects a band of predicted size in cell lysates of RT-4 and U-251 MG.

Anti-ANLN antibody AMAb90660 shows strong nuclear immunoreactivity in a subset of tumour cells in lung adenocarcinoma and a band of predicted size in human cell line U-251 MG.

AMAb90662 Anti-ANLN antibody shows strong nuclear immunoreactivity in a subset of tumor cells in colorectal cancer and a band of predicted size in human U-251 MG cells.


Figure 1
Kaplan-Meier (survival) analysis of recurrence free- **(A)** and breast cancer specific survival **(B)** according to aniliin expression for breast cancer patients. Patients were split into two groups based on high and low anillin expression.

1. O´Leary PC *et al.* Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer. *BMC Cancer*. 2013 Apr 2;13:175.

Co-Development Program

Research remains at the heart of Atlas Antibodies. We welcome customers to contact us for possible collaborations on both existing and future product offerings.

Atlas Antibodies invite you to participate in our Monoclonal Antibody Development Program. If you are looking for mouse monoclonal antibodies currently not available in our catalog, and if you are interested in developing the antibody together with us, please send in your project proposal to us.

Upon agreement to proceed with a collaboration, Atlas Antibodies will develop and produce the monoclonal antibody using the same procedures as for PrecisA Monoclonals. As part of this procedure, we epitope map all our clones to obtain unique clones with defined epitopes for final characterization.

The selection of the optimal clones for specific applications is made in collaboration with you. Antibodies will be sent to you for additional characterization in your laboratory, or Atlas Antibodies will make the characterization at our facilities with your expert input and/or material.

Atlas Antibodies cover all other development costs. If the project results in a commercialized product, it will be added to Atlas Antibodies PrecisA Monoclonal product portfolio and available to you.

All antibodies will be used for staining of a multitude of human tissues by the Human Protein Atlas (HPA) project, and these results will be available on the HPA web portal.

Benefits of the program

Atlas Antibodies take the full development cost while you get a discounted antibody with proven functionality in your experimental set-up.

For more information and/or requests for participating in the program, you are welcome to contact us at contact@atlasantibodies.com.

We are looking forward to hearing from you.

Collaboration project for SOX11

PrecisA Monoclonals against SOX11 (AMAb90501 and AMAb90502) were developed in collaboration with Dr Antonio Martinez (Laboratory of Pathology, Hospital Clínic, University of Barcelona, Spain).

Dr. Martinez is involved in the study of aggressive lymphomas, mechanisms of transformation, progression and prognostic factors. He has collaborated in the description of transcription factors involved in B-cell development and lymphomagenesis with special emphasis in those related in late B-cell differentiation pathways such as IRF4, IRF8, XBP1 and SOX11. His lab has long expertise in the characterization of antibodies for clinical use in hematopathology.

SOX11

This gene encodes a member of the group C SOX (SRY-related HMG-box) transcription factor family involved in the regulation of embryonic development and in the determination of the cell fate. The encoded protein may act as a transcriptional regulator after forming a protein complex with other proteins. The protein may function in the developing nervous system and play a role in tumorigenesis and adult neurogenesis.

Diseases associated with SOX11 include mantle cell lymphoma (MCL), lymphoblastic lymphoma, Burkitt lymphoma and malignant glioma. The diagnosis of mantle cell lymphoma can be difficult, especially in Cyclin D1 negative cases and the transcription factor SOX11 may serve as an important diagnostic marker. For this purpose, there is a need of a reliable Anti-SOX11 antibody in the clinical setting.

Tonsil involved by a Classical Mantle cell lymphoma, cyclin D1 negative in a 50 yo male. SOX11 staining (AMAb90501, clone CL0142; Atlas Antibodies).

Lymph node involvement by Classical Mantle cell lymphoma positive for Cyclin D1 in a 64 yo male. SOX11 is expressed in virtually all tumor cells. (AMAb90502, clone CL0143; Atlas Antibodies).

Soldini D *et al.* Assessment of SOX11 Expression in Routine Lymphoma Tissue Sections: Characterization of New Monoclonal Antibodies for Diagnosis of Mantle Cell Lymphoma. *Am J Surg Pathol.* 2013 Oct 18.

VERY RELIABLE ANTIBODIES

Atlas Antibodies manufactures and provides over 21,000 highly validated monoclonal and polyclonal primary antibodies and control antigens targeting the majority of human proteins for tissue and cell analysis to explore and accelerate research in biology, pathology, and medicine. The portfolio covers different research areas such as neuroscience, cancer, cell biology, stem cell & development. All our products are rigorously evaluated for specificity, reproducibility and performance and characterized for use in IHC, WB, and ICC-IF. Enhanced validation is applied as an extra level of security of antibody specificity in a defined context. Available as 25 µL and 100 µL unit size.

CREATED BY THE HUMAN PROTEIN ATLAS

With our roots in the Human Protein Atlas project, an integration of antibody-based imaging, proteomics, and transcriptomics, our antibodies are affinity-purified, reproducible, selective, and specific for their target proteins through our enhanced validation process. Our Triple A Polyclonals™ are developed within the Human Protein Atlas project.

VALIDATED BY ENHANCED VALIDATION

We take great care to validate our antibodies in IHC, WB, and ICC-IF. Our antibodies are validated in all major human tissues and organs and 20 cancer tissues. Each antibody is supported by over 500 staining images. As an additional layer of security, we perform Enhanced Validation. By using 5 different enhanced validation methods we validate our antibodies for each combination of protein, sample, and application. Discover our Triple A Polyclonals™ and PrecisA Monoclonals™ antibodies targeting the majority of human proteins in cells, tissues, and organs.

EVIDENCED BY SCIENCE

Made by researchers for researchers our products are used worldwide and referenced in 1000s of scientific peer-reviewed papers.

WE SUPPORT YOUR RESEARCH

Our scientific content and newsletter provide you with timely information about new product releases, research highlights, and much more. In addition, from our website you can download informative white papers, protocols, guides, posters, infographics, roundups of recent research papers, read blog posts and interviews.

HOW TO BUY OUR PRODUCTS

Our products are available worldwide. We deliver to all destinations in Europe (excluding Russia), US, Canada, Australia, New Zealand and Israel. We expand our offering through trusted partners worldwide.

You can **shop our full catalog online** or **find your local supplier**.

Atlas Antibodies Advanced Polyclonals.
Triple A Polyclonals™ are rabbit polyclonal primary antibodies developed within the Human Protein Atlas project. IHC characterization data from 44 normal and 20 cancer tissues is available on the Human Protein Atlas portal.


Precise. Accurate.Targeted.
PrecisA Monoclonals™ are mouse monoclonal primary antibodies developed against a number of carefully selected targets. Clones are selected to recognize only unique non-overlapping epitopes and isotypes.

PrEST Antigens

Recombinant protein fragments
PrEST Antigens™ are used as immunogens for the generation of Triple A Polyclonals and PrecisA Monoclonals.

Anti-MYH11 (HPA015310) in human breast tissue.

ATLAS ANTIBODIES

Atlas Antibodies AB
Voltavägen 13A
16869 Bromma, Sweden
atlasantibodies.com

Phone   +46(0)8 54 59 58 50
contact@atlasantibodies.com
order@atlasantibodies.com
support@atlasantibodies.com